OnCo Edge

Paper: Benefit from perioperative enfortumab vedotin-pembrolizumab in cisplatin-eligible MIBC.

2026-10-01T00:00:00Z

Published in Nat Rev Clin Oncol on 1 October 2026; matched the OnCo record for Enfortumab vedotin.

1 October 2026, Nat Rev Clin Oncol.

On OnCo: Enfortumab vedotin

Paper: HCT-ASCT confirmed as standard-of-care consolidation therapy for PCNSL.

2026-10-01T00:00:00Z

Published in Nat Rev Clin Oncol on 1 October 2026; matched the OnCo record for Primary CNS lymphoma.

1 October 2026, Nat Rev Clin Oncol.

On OnCo: Primary CNS lymphoma

Approval: FDA approves belzutifan in combination with lenvatinib for advanced renal cell carcinoma with a clear cell component

2026-09-24T00:00:00Z

On September 24, 2026, the Food and Drug Administration approved belzutifan (Welireg, Merck & Co., Inc.) in combination with lenvatinib (Lenvima, Eisai Inc.) for adults with advanced renal cell carcinoma with a clear cell component (ccRCC) following a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor.

24 September 2026, FDA.

On OnCo: Lenvatinib, Belzutifan, Renal cell carcinoma, Clear cell renal cell carcinoma, Spinal cord tumours, Pancreatic neuroendocrine tumours, Hereditary pheochromocytoma and paraganglioma, Hepatocellular carcinoma, Advanced hepatocellular carcinoma, Intermediate hepatocellular carcinoma, Thyroid cancer

Approval: FDA approves lirafugratinib for previously treated, unresectable, locally advanced or metastatic cholangiocarcinoma

2026-09-23T00:00:00Z

On September 23, 2026, the Food and Drug Administration approved lirafugratinib (Lyrfigtu, Elevar Therapeutics, Inc.), a kinase inhibitor, for the treatment of adults with previously treated unresectable, locally advanced or metastatic cholangiocarcinoma harboring a fibroblast growth factor receptor 2 (FGFR2) gene fusion or other rearrangement.

23 September 2026, FDA.

On OnCo: Lirafugratinib, Biliary tract cancer, FGFR2

Issue: OnCo weekly, 2026-10-03

2026-10-03T00:00:00Z

846 changelog entries, 1 upcoming date, 8 corrections.

3 October 2026, OnCo weekly issue.

Proposal: Proposed approval: Aspirin

2026-10-03T00:00:00Z

openFDA has a label for "Aspirin".

3 October 2026, FDA.

On OnCo: Aspirin, Danazol, Givinostat, Ivermectin, Metyrapone, Mifepristone, Nicotinamide, Pancrelipase

Proposal: Proposed new product: Casgevy

2026-10-03T00:00:00Z

EMA register: Casgevy (exagamglogene autotemcel) Authorised, 2024-02-09.

3 October 2026, EMA.

Proposal: Proposed new product: Cystagon

2026-10-03T00:00:00Z

EMA register: Cystagon (mercaptamine bitartrate) Authorised, 1997-06-23.

3 October 2026, EMA.

Proposal: Proposed new product: Entyvio

2026-10-03T00:00:00Z

EMA register: Entyvio (vedolizumab) Authorised, 2014-05-22.

3 October 2026, EMA.

Proposal: Proposed new product: Libmeldy

2026-10-03T00:00:00Z

EMA register: Libmeldy (autologous CD34+ cells encoding ARSA gene) Authorised, 2020-12-17.

3 October 2026, EMA.

Proposal: Proposed new product: Lumeblue

2026-10-03T00:00:00Z

EMA register: Lumeblue (previously Methylthioninium chloride Cosmo) (methylthioninium chloride) Authorised, 2020-08-19.

3 October 2026, EMA.

Proposal: Proposed new product: Lynkuet

2026-10-03T00:00:00Z

EMA register: Lynkuet (elinzanetant) Authorised, 2025-11-17.

3 October 2026, EMA.

Proposal: Proposed new product: NeoRecormon

2026-10-03T00:00:00Z

EMA register: NeoRecormon (epoetin beta) Authorised, 1997-07-16.

3 October 2026, EMA.

Proposal: Proposed new product: Nezglyal

2026-10-03T00:00:00Z

EMA register: Nezglyal (leriglitazone) Authorised, 2026-09-21.

3 October 2026, EMA.

Proposal: Proposed new product: Procysbi

2026-10-03T00:00:00Z

EMA register: Procysbi (mercaptamine) Authorised, 2013-09-05.

3 October 2026, EMA.

Proposal: Proposed new product: SomaKit TOC

2026-10-03T00:00:00Z

EMA register: SomaKit TOC (edotreotide) Authorised, 2016-12-08.

3 October 2026, EMA.

Proposal: Proposed new product: Strimvelis

2026-10-03T00:00:00Z

EMA register: Strimvelis (autologous CD34+ enriched cell fraction that contains CD34+ cells transduced with retroviral vector that encodes for the human ADA cDNA sequence) Authorised, 2016-05-26.

3 October 2026, EMA.

Proposal: Proposed new product: Waskyra

2026-10-03T00:00:00Z

EMA register: Waskyra (etuvetidigene autotemcel) Authorised, 2026-01-09.

3 October 2026, EMA.

Proposal: Proposed new product: Xromi

2026-10-03T00:00:00Z

EMA register: Xromi (hydroxycarbamide) Authorised, 2019-07-01.

3 October 2026, EMA.

Proposal: Proposed new product: Yartemlea

2026-10-03T00:00:00Z

EMA register: Yartemlea (Narsoplimab) Opinion under re-examination.

3 October 2026, EMA.

Proposal: Proposed new product: Zefylti

2026-10-03T00:00:00Z

EMA register: Zefylti (filgrastim) Application withdrawn.

3 October 2026, EMA.

Proposal: Proposed trial status change: ALKOVE-1

2026-10-03T00:00:00Z

ClinicalTrials.gov overall status is RECRUITING; recorded positive.

3 October 2026, ClinicalTrials.gov.

On OnCo: ALKOVE-1

Proposal: Proposed trial status change: Alliance A071401

2026-10-03T00:00:00Z

ClinicalTrials.gov overall status is RECRUITING; recorded positive.

3 October 2026, ClinicalTrials.gov.

On OnCo: Alliance A071401

Proposal: Proposed trial status change: AUGMENT-101

2026-10-03T00:00:00Z

ClinicalTrials.gov overall status is RECRUITING; recorded positive.

3 October 2026, ClinicalTrials.gov.

On OnCo: AUGMENT-101

Proposal: Proposed trial status change: Bonner trial

2026-10-03T00:00:00Z

ClinicalTrials.gov overall status is TERMINATED; recorded positive.

3 October 2026, ClinicalTrials.gov.

On OnCo: Bonner trial

Issue: OnCo weekly, 2026-10-02

2026-10-02T00:00:00Z

825 changelog entries, 1 upcoming date, 8 corrections.

2 October 2026, OnCo weekly issue.

Paper: Erratum: Five-Year Outcomes of Short-Term Radiotherapy Plus Chemotherapy Versus Long-Term Chemoradiotherapy for Locally Advanced Rectal Cancer: Updated Results of the STELLAR Trial.

2026-09-25T00:00:00Z

Published in J Clin Oncol on 25 September 2026; found by the roadmap watch for STELLAR.

25 September 2026, J Clin Oncol.

On OnCo: STELLAR, Devices and physical therapies roadmap: heat and light → electric fields and focused sound → drug-releasing implants

Approval: FDA approves imlunestrant in combination with abemaciclib for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer

2026-09-18T00:00:00Z

On September 18, 2026, the Food and Drug Administration approved imlunestrant (Inluriyo) in combination with abemaciclib (Verzenio), for adults with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, estrogen receptor 1 (ESR1)-mutated advanced or metastatic breast cancer, as detected by an FDA-authorized test, with disease progression following at least one line of endocrine therapy.

18 September 2026, FDA.

On OnCo: Imlunestrant, Abemaciclib, HR-positive / HER2-negative breast cancer, Breast cancer, High-risk early HR-positive breast cancer, HR-positive metastatic breast cancer after CDK4/6 inhibitors, CDK4/6, Estrogen receptor

Paper: [Clues for identifying Diamond-Blackfan anemia among infants with early severe anemia: Clinical and genetic analysis of 11 cases].

2026-10-01T00:00:00Z

Published in Zhonghua Yi Xue Yi Chuan Xue Za Zhi on 1 October 2026; matched the OnCo record for RPS19.

1 October 2026, Zhonghua Yi Xue Yi Chuan Xue Za Zhi.

On OnCo: RPS19, RPS29

Paper: Adolescent health across Asia Pacific, 2000-23: a systematic analysis for the Global Burden of Disease Study 2023.

2026-10-01T00:00:00Z

Published in Lancet Child Adolesc Health on 1 October 2026; matched the OnCo record for Logic-gated therapeutics.

1 October 2026, Lancet Child Adolesc Health.

On OnCo: Logic-gated therapeutics

Paper: Analysis of end-stage renal disease mediated by cuproptosis-related genes.

2026-10-01T00:00:00Z

Published in Clin Nephrol on 1 October 2026; matched the OnCo record for ATP7B.

1 October 2026, Clin Nephrol.

On OnCo: ATP7B, DLST

Paper: Approaches to thyroid nodules in paediatric cancer predisposition syndromes.

2026-10-01T00:00:00Z

Published in Eur Thyroid J on 1 October 2026; matched the OnCo record for DICER1.

1 October 2026, Eur Thyroid J.

On OnCo: DICER1

Paper: ASO Visual Abstract: A Prospective Multicenter Comparative Cohort Study of Neoadjuvant Sintilimab Plus Chemotherapy and Chemoradiotherapy in Resectable Clinical Node-Positive Esophageal Squamous Cell Carcinoma.

2026-10-01T00:00:00Z

Published in Ann Surg Oncol on 1 October 2026; matched the OnCo record for Sintilimab.

1 October 2026, Ann Surg Oncol.

On OnCo: Sintilimab

Paper: ASO Visual Abstract: Mex3a Stabilizes INHBB mRNA to Activate SMAD-Signaling and Promote Hepatocellular Carcinoma Metastasis.

2026-10-01T00:00:00Z

Published in Ann Surg Oncol on 1 October 2026; matched the OnCo record for INHBB.

1 October 2026, Ann Surg Oncol.

On OnCo: INHBB

Paper: ASO Visual Abstract: Prognostic Value of Intratumoral Expression of Claudin 18.2 in Resected Pancreatic Cancer.

2026-10-01T00:00:00Z

Published in Ann Surg Oncol on 1 October 2026; matched the OnCo record for Claudin 18.2.

1 October 2026, Ann Surg Oncol.

On OnCo: Claudin 18.2

Paper: ASO Visual Abstract: Treatment for Oligo-recurrence of Diffuse Pleural Mesothelioma After Extended Pleurectomy/Decortication.

2026-10-01T00:00:00Z

Published in Ann Surg Oncol on 1 October 2026; matched the OnCo record for Pleural mesothelioma.

1 October 2026, Ann Surg Oncol.

On OnCo: Pleural mesothelioma

Paper: Association Between Danish Guideline Treatments for Breast Cancer and Physiotherapy-Relevant Late Effects: A Nationwide Cohort Study.

2026-10-01T00:00:00Z

Published in Physiother Res Int on 1 October 2026; matched the OnCo record for Sentinel lymph node biopsy.

1 October 2026, Physiother Res Int.

On OnCo: Sentinel lymph node biopsy

Paper: ATP Release and Purinergic Signaling Potentiate β-Adrenergic Effects on Brown Adipocytes.

2026-10-01T00:00:00Z

Published in Acta Physiol (Oxf) on 1 October 2026; matched the OnCo record for MPEG1.

1 October 2026, Acta Physiol (Oxf).

On OnCo: MPEG1

Paper: Blinatumomab-induced catastrophic immune effector cell-associated neurotoxicity with diffuse cerebral edema in a patient with ALL: Case report.

2026-10-01T00:00:00Z

Published in Int J Clin Pharmacol Ther on 1 October 2026; matched the OnCo record for AFF1.

1 October 2026, Int J Clin Pharmacol Ther.

On OnCo: AFF1, Blinatumomab

Paper: Cell Type-Specific Roles of TBK1 in Steatotic Liver Disease: Evidence for an Inflammatory TBK1+CASP1+ Kupffer Cell State.

2026-10-01T00:00:00Z

Published in Liver Int on 1 October 2026; matched the OnCo record for TBK1.

1 October 2026, Liver Int.

On OnCo: TBK1

Paper: Commissioning and end-to-end validation of a combined surface-guided and triggered kV imaging workflow for breath-hold SBRT on a Varian TrueBeam.

2026-10-01T00:00:00Z

Published in J Appl Clin Med Phys on 1 October 2026; matched the OnCo record for In-room imaging for radiotherapy.

1 October 2026, J Appl Clin Med Phys.

On OnCo: In-room imaging for radiotherapy

Paper: Conformational stability and domain-specific structural features of tumor autoantigens regulate autoantibody epitope propensity.

2026-10-01T00:00:00Z

Published in Protein Sci on 1 October 2026; matched the OnCo record for CTAG1B.

1 October 2026, Protein Sci.

On OnCo: CTAG1B, WT1

Paper: Correction to 'FOLFOX Versus FOLFIRI as Second-Line Chemotherapy in Patients With Advanced Biliary Tract Cancers: A Multicenter, Italian Study'.

2026-10-01T00:00:00Z

Published in Liver Int on 1 October 2026; matched the OnCo record for FOLFIRI.

1 October 2026, Liver Int.

On OnCo: FOLFIRI, FOLFOX

Paper: Cross-Talk Between Histamine H2 Receptor and Glucocorticoid Receptor: Potential Implications in Acute Myeloid Leukemia Treatment.

2026-10-01T00:00:00Z

Published in Pharmacol Res Perspect on 1 October 2026; matched the OnCo record for Cytarabine.

1 October 2026, Pharmacol Res Perspect.

On OnCo: Cytarabine

Paper: CX3CR1 Modulates Migration of Resident Microglia Towards Cortical Laser-Induced Lesions.

2026-10-01T00:00:00Z

Published in Glia on 1 October 2026; matched the OnCo record for CX3CL1.

1 October 2026, Glia.

On OnCo: CX3CL1

Paper: Effects of curcumin and nicorandil on nilotinib-induced QT interval prolongation in rats: A telemetry-based study.

2026-10-01T00:00:00Z

Published in Pak J Pharm Sci on 1 October 2026; matched the OnCo record for Nilotinib.

1 October 2026, Pak J Pharm Sci.

On OnCo: Nilotinib

Paper: Effects of Progressive Inspiratory Muscle Training on Lung Volume and Respiratory Strength in Patients With Pre-Dialysis Chronic Kidney Disease.

2026-10-01T00:00:00Z

Published in Physiother Res Int on 1 October 2026; matched the OnCo record for Inflammatory myofibroblastic tumour.

1 October 2026, Physiother Res Int.

On OnCo: Inflammatory myofibroblastic tumour

Paper: Elevated Expression of Caveolin-1 Reflects a Poor Prognosis in Patients With Primary Central Nervous System Lymphomas.

2026-10-01T00:00:00Z

Published in Neuropathology on 1 October 2026; matched the OnCo record for Primary CNS lymphoma.

1 October 2026, Neuropathology.

On OnCo: Primary CNS lymphoma

Paper: Engineering a protein homodimer from a heterodimer: A chimeric DBHS protein.

2026-10-01T00:00:00Z

Published in Protein Sci on 1 October 2026; matched the OnCo record for PSPC1.

1 October 2026, Protein Sci.

On OnCo: PSPC1, SFPQ

Paper: Estradiol Promotes Tumor Progression in ERα-Low Endometrial Cancer via the GPER/SphK1 Pathway.

2026-10-01T00:00:00Z

Published in J Biochem Mol Toxicol on 1 October 2026; matched the OnCo record for CCNE1.

1 October 2026, J Biochem Mol Toxicol.

On OnCo: CCNE1, SPHK1

Paper: Evaluation of interfractional shift corrections in Gamma Knife radiosurgery.

2026-10-01T00:00:00Z

Published in J Appl Clin Med Phys on 1 October 2026; matched the OnCo record for Gamma Knife.

1 October 2026, J Appl Clin Med Phys.

On OnCo: Gamma Knife

Paper: External validation of the NADIR model for early prostate-specific antigen response prediction in enzalutamide-treated metastatic hormone-sensitive prostate cancer: An analysis of the ARCHES trial.

2026-10-01T00:00:00Z

Published in Cancer on 1 October 2026; found by the roadmap watch for ARCHES.

1 October 2026, Cancer.

On OnCo: ARCHES, Hormonal therapy roadmap: removing the ovaries → tamoxifen → oral degraders switched by a blood test

Paper: Feasibility of lattice radiation therapy using a noncoplanar vertex arrangement and dynamic conformal arcs.

2026-10-01T00:00:00Z

Published in J Appl Clin Med Phys on 1 October 2026; matched the OnCo record for VDR.

1 October 2026, J Appl Clin Med Phys.

On OnCo: VDR

Paper: Fertility-Sparing Treatment of Endometrial Cancer: Survey of Australian Practice.

2026-10-01T00:00:00Z

Published in Aust N Z J Obstet Gynaecol on 1 October 2026; matched the OnCo record for Progestins.

1 October 2026, Aust N Z J Obstet Gynaecol.

On OnCo: Progestins, POLE

Paper: FOCS-24: An integrated oncologic-functional endpoint and its preoperative nomogram after focal therapy for localized prostate cancer.

2026-10-01T00:00:00Z

Published in Urol Oncol on 1 October 2026; matched the OnCo record for Multiparametric prostate MRI.

1 October 2026, Urol Oncol.

On OnCo: Multiparametric prostate MRI

Paper: Fruquintinib: Mechanism of Action, Clinical, and Translational Science.

2026-10-01T00:00:00Z

Published in Clin Transl Sci on 1 October 2026; matched the OnCo record for Fruquintinib.

1 October 2026, Clin Transl Sci.

On OnCo: Fruquintinib

Paper: Gender-Specific Cancer-Related Survival Analysis of Robotic Versus Laparoscopic Low Anterior Resection for Rectal Adenocarcinoma: A Multicenter Study.

2026-10-01T00:00:00Z

Published in Int J Med Robot on 1 October 2026; matched the OnCo record for Luminal androgen receptor triple-negative breast cancer.

1 October 2026, Int J Med Robot.

On OnCo: Luminal androgen receptor triple-negative breast cancer

Paper: Ginsenosides Rb1 and Rg1 Suppress Lipopolysaccharide-Induced Inflammatory Gene Expression in Microglia and Astrocytes, Unlike Rb2.

2026-10-01T00:00:00Z

Published in Pharmacol Res Perspect on 1 October 2026; matched the OnCo record for RB1.

1 October 2026, Pharmacol Res Perspect.

On OnCo: RB1

Paper: Gut Microbiome Diversity, Functional Potential, and Ecological Relevance of Hottentotta tamulus.

2026-10-01T00:00:00Z

Published in Microbiologyopen on 1 October 2026; matched the OnCo record for MT-CO1.

1 October 2026, Microbiologyopen.

On OnCo: MT-CO1

Paper: Immune Checkpoint Inhibitor-Associated Hemophagocytic Lymphohistiocytosis: Clinical Presentation and Outcomes in Three Patients.

2026-10-01T00:00:00Z

Published in J Immunother on 1 October 2026; matched the OnCo record for Tocilizumab.

1 October 2026, J Immunother.

On OnCo: Tocilizumab

Paper: Impact of post-chemotherapy classification on outcomes in stage III and IV unilateral favorable histology Wilms tumor: Pooled data from Children's Oncology Group AREN0532, AREN0533, and AREN03B2 studies.

2026-10-01T00:00:00Z

Published in Cancer on 1 October 2026; matched the OnCo record for Advanced-stage classical Hodgkin lymphoma.

1 October 2026, Cancer.

On OnCo: Advanced-stage classical Hodgkin lymphoma

Paper: Inhibition of Acetylation Activity of p300/CBP Ameliorates Hepatic Steatosis Through Downregulation of ACSL4.

2026-10-01T00:00:00Z

Published in Liver Int on 1 October 2026; matched the OnCo record for EP300.

1 October 2026, Liver Int.

On OnCo: EP300

Paper: Insulin autoimmune syndrome (Hirata Disease): An updated review of epidemiology, pathophysiology, clinical features, diagnosis, and management.

2026-10-01T00:00:00Z

Published in Dis Mon on 1 October 2026; matched the OnCo record for Pancreatic neuroendocrine tumours.

1 October 2026, Dis Mon.

On OnCo: Pancreatic neuroendocrine tumours

Paper: Integrated Assessment of Sarcopenia in Patients with Gastric Cancer Using Deep Learning and Radiomics.

2026-10-01T00:00:00Z

Published in J Cachexia Sarcopenia Muscle on 1 October 2026; matched the OnCo record for CT body composition and sarcopenia measurement.

1 October 2026, J Cachexia Sarcopenia Muscle.

On OnCo: CT body composition and sarcopenia measurement

Paper: Integrated omics-driven discovery reveals synphilin-1-mediated anoikis resistance through p53 down-regulation.

2026-10-01T00:00:00Z

Published in Biosci Rep on 1 October 2026; matched the OnCo record for SNCAIP.

1 October 2026, Biosci Rep.

On OnCo: SNCAIP

Paper: Macrophage FOXO1 Inhibition Protects Against Hyperglycaemia-Associated Kidney Injury.

2026-10-01T00:00:00Z

Published in Basic Clin Pharmacol Toxicol on 1 October 2026; matched the OnCo record for FOXO1.

1 October 2026, Basic Clin Pharmacol Toxicol.

On OnCo: FOXO1

Paper: Management of Hemangiomas.

2026-10-01T00:00:00Z

Published in Clin Plast Surg on 1 October 2026; matched the OnCo record for Propranolol.

1 October 2026, Clin Plast Surg.

On OnCo: Propranolol

Paper: MiR-376c-3p Targets STRBP mRNA to Regulate Cashmere Goat Hair Follicle Stem Cell Proliferation and Multipotency by Inhibiting the Wnt/β-Catenin and BMP Signaling Pathways.

2026-10-01T00:00:00Z

Published in Anim Genet on 1 October 2026; matched the OnCo record for SOX9.

1 October 2026, Anim Genet.

On OnCo: SOX9

Paper: New Observations on a Low-Grade Diffusely Infiltrative Tumour, SMARCB1 Mutant, Arguing for a New Tumour Type.

2026-10-01T00:00:00Z

Published in Neuropathol Appl Neurobiol on 1 October 2026; matched the OnCo record for SMARCB1.

1 October 2026, Neuropathol Appl Neurobiol.

On OnCo: SMARCB1

Paper: Non-Meningothelial Mesenchymal Tumor of the Central Nervous System: Case Report and Literature Review.

2026-10-01T00:00:00Z

Published in Neuropathology on 1 October 2026; matched the OnCo record for CIC.

1 October 2026, Neuropathology.

On OnCo: CIC

Paper: Nutritional Indexes and Their Variations as Predictors of Atezolizumab Plus Chemotherapy Efficacy in Extensive-Stage Small Cell Lung Cancer: A Turkish Oncology Group Study.

2026-10-01T00:00:00Z

Published in J Immunother on 1 October 2026; matched the OnCo record for Extensive-stage small-cell lung cancer.

1 October 2026, J Immunother.

On OnCo: Extensive-stage small-cell lung cancer, Platinum + etoposide

Issue: OnCo weekly, 2026-10-01

2026-10-01T00:00:00Z

810 changelog entries, 1 upcoming date, 12 corrections.

1 October 2026, OnCo weekly issue.

Paper: Oral vitamin C supplementation in patients with clonal cytopenia of undetermined significance or lower-risk myeloid malignancies: Results from EVITA, a phase 2 randomized, placebo-controlled trial.

2026-10-01T00:00:00Z

Published in Cancer on 1 October 2026; matched the OnCo record for TET2.

1 October 2026, Cancer.

On OnCo: TET2

Paper: Pancreatic Cancer Disrupts Circadian Patterns of Gene Expression in Cardiorespiratory Muscles.

2026-10-01T00:00:00Z

Published in J Cachexia Sarcopenia Muscle on 1 October 2026; matched the OnCo record for REST.

1 October 2026, J Cachexia Sarcopenia Muscle.

On OnCo: REST

Paper: Precision Oncology in Soft Tissue Sarcomas and Gastrointestinal Stromal Tumors.

2026-10-01T00:00:00Z

Published in Hematol Oncol Clin North Am on 1 October 2026; matched the OnCo record for Gastrointestinal stromal tumour.

1 October 2026, Hematol Oncol Clin North Am.

On OnCo: Gastrointestinal stromal tumour

Paper: Predicting Relevant Microglia-Associated Cell-Cell Communication Pathways in Alzheimer's Disease: A Role for SPP1.

2026-10-01T00:00:00Z

Published in Glia on 1 October 2026; matched the OnCo record for AXL.

1 October 2026, Glia.

On OnCo: AXL, GAS6, ITGAV

Paper: Prevalence and Clinical Significance of Abnormal Findings on Pre-Diagnostic Imaging in Pancreatic Ductal Adenocarcinoma.

2026-10-01T00:00:00Z

Published in Pancreas on 1 October 2026; matched the OnCo record for Intraductal papillary mucinous neoplasm and other pancreatic cystic precursors.

1 October 2026, Pancreas.

On OnCo: Intraductal papillary mucinous neoplasm and other pancreatic cystic precursors

Paper: Primary Cerebral Pleomorphic-Myxoid Sarcoma With Many Hyaline Globules.

2026-10-01T00:00:00Z

Published in Neuropathology on 1 October 2026; matched the OnCo record for DICER1.

1 October 2026, Neuropathology.

On OnCo: DICER1

Paper: Primary pulmonary salivary gland-type tumors in cytopathology practice: A systematic review and meta-analysis.

2026-10-01T00:00:00Z

Published in Cancer Cytopathol on 1 October 2026; matched the OnCo record for Mucoepidermoid carcinoma.

1 October 2026, Cancer Cytopathol.

On OnCo: Mucoepidermoid carcinoma, Salivary gland cancers

Paper: PSEN1 Expression Identifies a Developmentally Distinct Favourable-Prognosis State in SHH α Medulloblastoma.

2026-10-01T00:00:00Z

Published in Int J Dev Neurosci on 1 October 2026; matched the OnCo record for Gamma-secretase.

1 October 2026, Int J Dev Neurosci.

On OnCo: Gamma-secretase, Medulloblastoma

Paper: Pulmonary Tuberculosis in Rhesus Macaque (Macaca mulatta): A Case Report.

2026-10-01T00:00:00Z

Published in J Med Primatol on 1 October 2026; matched the OnCo record for Medullary thyroid cancer.

1 October 2026, J Med Primatol.

On OnCo: Medullary thyroid cancer

Paper: Research on the impact of different chemotherapy and targeted therapy regimens on postoperative disease-free survival in breast cancer patients.

2026-10-01T00:00:00Z

Published in Pak J Pharm Sci on 1 October 2026; matched the OnCo record for Capecitabine.

1 October 2026, Pak J Pharm Sci.

On OnCo: Capecitabine

Paper: Resolution and Quantitation of Ribonucleosides and Deoxyribonucleosides in Digested Genomic DNA by UHPLC-MS/MS.

2026-10-01T00:00:00Z

Published in Biomed Chromatogr on 1 October 2026; matched the OnCo record for Ceralasertib.

1 October 2026, Biomed Chromatogr.

On OnCo: Ceralasertib

Paper: Responsiveness, Smallest Detectable Change, and Minimal Important Change of the Turkish Pelvic Floor Distress Inventory-20 Following Pelvic Floor Muscle Training.

2026-10-01T00:00:00Z

Published in Physiother Res Int on 1 October 2026; matched the OnCo record for Salivary duct carcinoma.

1 October 2026, Physiother Res Int.

On OnCo: Salivary duct carcinoma

Paper: Sequence Inversion Dictates the Antiproliferative Activity of Bidirectional Tryptophan-Containing Dipeptide Libraries.

2026-10-01T00:00:00Z

Published in J Pept Sci on 1 October 2026; matched the OnCo record for Mia.

1 October 2026, J Pept Sci.

On OnCo: Mia

Paper: Talimogene Laherparepvec Response in Recurrent Melanoma During Corticosteroid Replacement for Immune Checkpoint Inhibitor-Induced Adrenal Insufficiency: A Case Report.

2026-10-01T00:00:00Z

Published in J Immunother on 1 October 2026; matched the OnCo record for Talimogene laherparepvec.

1 October 2026, J Immunother.

On OnCo: Talimogene laherparepvec

Paper: The use of locoregional therapies in cholangiocarcinoma.

2026-10-01T00:00:00Z

Published in J Hepatol on 1 October 2026; matched the OnCo record for Floxuridine.

1 October 2026, J Hepatol.

On OnCo: Floxuridine, Radioembolisation, Transarterial chemoembolisation

Paper: Understanding Barriers and Motivators of Familial Hypercholesterolemia Genetic Testing: Insights From the Singapore Public.

2026-10-01T00:00:00Z

Published in J Genet Couns on 1 October 2026; matched the OnCo record for FH.

1 October 2026, J Genet Couns.

On OnCo: FH

Paper: Weird, Witty and Worthwhile: Exploring the Benefits of Mnemonic-Based Medical Education.

2026-10-01T00:00:00Z

Published in Clin Teach on 1 October 2026; matched the OnCo record for Small intestine cancer.

1 October 2026, Clin Teach.

On OnCo: Small intestine cancer

Issue: OnCo weekly, 2026-09-30

2026-09-30T00:00:00Z

797 changelog entries, 1 upcoming date, 14 corrections.

30 September 2026, OnCo weekly issue.

Issue: OnCo weekly, 2026-09-29

2026-09-29T00:00:00Z

802 changelog entries, 1 regulatory event, 1 upcoming date, 8 corrections.

29 September 2026, OnCo weekly issue.

Paper: Performance and safety of a multi-cancer early detection test: the PATHFINDER 2 study.

2026-09-22T00:00:00Z

Published in Nat Med on 22 September 2026; found by the roadmap watch for PATHFINDER 2.

22 September 2026, Nat Med.

On OnCo: PATHFINDER 2, ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment, Early detection roadmap: organ screening → blood tests for many cancers

Paper: Performance of a multi-cancer early detection test in the randomized controlled NHS-Galleri trial.

2026-09-22T00:00:00Z

Published in Nat Med on 22 September 2026; found by the roadmap watch for NHS-Galleri.

22 September 2026, Nat Med.

On OnCo: NHS-Galleri, ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment, Early detection roadmap: organ screening → blood tests for many cancers

Paper: Switching of transcriptional control from interferon regulatory factor 2 to interferon regulatory factor 1 drives innate immune cell activation.

2026-09-22T00:00:00Z

Published in Cell on 22 September 2026; matched the OnCo record for IRF1.

22 September 2026, Cell.

On OnCo: IRF1, SPOP

Paper: The liver niche accelerates, while the lung niche restrains secondary spread of breast cancer.

2026-09-22T00:00:00Z

Published in Cancer Discov on 22 September 2026; matched the OnCo record for BMP2.

22 September 2026, Cancer Discov.

On OnCo: BMP2

Issue: OnCo weekly, 2026-09-28

2026-09-28T00:00:00Z

795 changelog entries, 1 regulatory event, 1 upcoming date, 8 corrections.

28 September 2026, OnCo weekly issue.

Paper: Perspectives of women and healthcare providers on facilitators and barriers to cervical cancer screening in the rural Kilimanjaro region Tanzania: a qualitative study.

2026-09-28T00:00:00Z

Published on 28 September 2026 after first appearing as a preprint; matched CCDC6.

28 September 2026.

On OnCo: CCDC6

Paper: The relationship between activities of daily living, frailty, and care dependency in older adults with lung cancer.

2026-09-28T00:00:00Z

Published on 28 September 2026 after first appearing as a preprint; matched MET.

28 September 2026.

On OnCo: MET

Paper: Melatonin, circadian metabolism, mitochondrial remodeling, and cell size dynamics in primitive hematopoietic stem cells.

2026-09-21T00:00:00Z

Published in Blood on 21 September 2026; matched the OnCo record for LMNA.

21 September 2026, Blood.

On OnCo: LMNA

Paper: Acoustically Activatable Drug-Loaded Nanodroplets for Mechanochemical Therapy in Solid Tumors.

2026-09-27T00:00:00Z

Published on 27 September 2026 after first appearing as a preprint; matched Ultrasound.

27 September 2026.

On OnCo: Ultrasound

Paper: Is a Few Too Many? Alcohol Consumption and Prostate Cancer Upgrading During Active Surveillance.

2026-09-27T00:00:00Z

Published on 27 September 2026 after first appearing as a preprint; matched Active surveillance and ELL.

27 September 2026.

On OnCo: Active surveillance, ELL

Paper: Autoencoders for unsupervised analysis of rat myeloarchitecture.

2026-09-26T00:00:00Z

Published on 26 September 2026 after first appearing as a preprint; matched Pathology & radiology foundation models.

26 September 2026.

On OnCo: Pathology & radiology foundation models

Paper: Collagen targeting IL-12 combined with doxorubicin enhances the anti-tumor effect against osteosarcoma.

2026-09-26T00:00:00Z

Published on 26 September 2026 after first appearing as a preprint; matched Doxorubicin and VWF.

26 September 2026.

On OnCo: Doxorubicin, VWF

Paper: Primary ALK-positive anaplastic large cell lymphoma of the urinary bladder in a pediatric patient: a case report and review of literature.

2026-09-26T00:00:00Z

Published on 26 September 2026 after first appearing as a preprint; matched CD30, CT and ALK.

26 September 2026.

On OnCo: CD30, CT, ALK, Brentuximab vedotin

Paper: Stem cell morphology defines functional heterogeneity and therapeutic vulnerabilities in glioblastoma.

2026-09-26T00:00:00Z

Published on 26 September 2026 after first appearing as a preprint; matched Temozolomide, Single-cell & spatial profiling and Patient-derived organoids.

26 September 2026.

On OnCo: Temozolomide, Single-cell & spatial profiling, Patient-derived organoids, Spatial transcriptomics, State

Paper: Unexpected functional role of the transactivation domain for nuclear import of STAT5.

2026-09-26T00:00:00Z

Published on 26 September 2026 after first appearing as a preprint; matched Erythropoietin receptor and STAT5.

26 September 2026.

On OnCo: Erythropoietin receptor, STAT5

Paper: Converting lysosomes into photothermal organelles enables nanoparticle-free tumor ablation via intracellular vapor bubbles.

2026-09-25T00:00:00Z

Published on 25 September 2026 after first appearing as a preprint; matched Sunitinib.

25 September 2026.

On OnCo: Sunitinib

Paper: Evolution of occupational health risks among waste incinerator workers: A four-decade review.

2026-09-25T00:00:00Z

Published on 25 September 2026 after first appearing as a preprint; matched CFLAR.

25 September 2026.

On OnCo: CFLAR

Paper: FACT-(H3-H4) complex stimulates Pol α activity to coordinate DNA synthesis with nucleosome assembly.

2026-09-25T00:00:00Z

Published on 25 September 2026 after first appearing as a preprint; matched H3C14.

25 September 2026.

On OnCo: H3C14

Paper: Fast structural search for classification of gut bacterial mucin O-glycan degrading enzymes.

2026-09-25T00:00:00Z

Published on 25 September 2026 after first appearing as a preprint; matched State.

25 September 2026.

On OnCo: State

Paper: Fe3O4-Au cluster-satellite particles as direct colorimetric reporters in a smartphone-quantified lateral flow immunoassay for prostate-specific antigen.

2026-09-25T00:00:00Z

Published on 25 September 2026 after first appearing as a preprint; matched KLK2 and KLK3.

25 September 2026.

On OnCo: KLK2, KLK3

Paper: Interdisciplinary management and genetic evaluation of pediatric cancer predisposition syndromes: a retrospective cohort study.

2026-09-25T00:00:00Z

Published on 25 September 2026 after first appearing as a preprint; matched Germline (hereditary) testing.

25 September 2026.

On OnCo: Germline (hereditary) testing

Paper: Optical microscopy predictions of focal recurrence in glioblastoma.

2026-09-25T00:00:00Z

Published on 25 September 2026 after first appearing as a preprint; matched Cytotoxic chemotherapy.

25 September 2026.

On OnCo: Cytotoxic chemotherapy

Paper: PDLIM2 in lung adenocarcinoma metastasis.

2026-09-25T00:00:00Z

Published on 25 September 2026 after first appearing as a preprint; matched KRAS, TP53 and ELL.

25 September 2026.

On OnCo: KRAS, TP53, ELL

Paper: Proteomic study for the prediction of μ CT imaging with iodine.

2026-09-25T00:00:00Z

Published on 25 September 2026 after first appearing as a preprint; matched Atlas, FLG and SET.

25 September 2026.

On OnCo: Atlas, FLG, SET

Paper: Specific targeting of MR1-antigen complexes using nanobodies.

2026-09-25T00:00:00Z

Published on 25 September 2026 after first appearing as a preprint; matched Bispecific antibodies, CD3 and HLA-A.

25 September 2026.

On OnCo: Bispecific antibodies, CD3, HLA-A, MCLA-129

Paper: Two Glu/Asp residues cooperatively mediate an early step of ATP hydrolysis in GHKL ATPases MutL and GyrB.

2026-09-25T00:00:00Z

Published on 25 September 2026 after first appearing as a preprint; matched State, Mismatch repair proteins and MLH1.

25 September 2026.

On OnCo: State, Mismatch repair proteins, MLH1, PMS2, HSP90AA1

Paper: Association Between Patient-Reported Outcomes and Health Care Resource Utilization: Toward Developing Patient-Centered Value Measures in Cancer Care.

2026-09-18T00:00:00Z

Published in J Clin Oncol on 18 September 2026; matched the OnCo record for Early-stage classical Hodgkin lymphoma.

18 September 2026, J Clin Oncol.

On OnCo: Early-stage classical Hodgkin lymphoma

Paper: Phase III Trials Test First-Line Options in Advanced NSCLC.

2026-09-18T00:00:00Z

Published in Cancer Discov on 18 September 2026; matched the OnCo record for Amivantamab.

18 September 2026, Cancer Discov.

On OnCo: Amivantamab, Ivonescimab, Zipalertinib

Paper: γδ T cells modulate anti-tumor immunity in small cell lung cancer.

2026-09-18T00:00:00Z

Published in Cancer Cell on 18 September 2026; matched the OnCo record for Zoledronic acid.

18 September 2026, Cancer Cell.

On OnCo: Zoledronic acid, Single-cell & spatial profiling, T-cell engagers, DLL3, CD3, PD-1, PD-L1

Paper: A CRISPR-Based Humanized Model Reveals Cooperative Role of STAG2 Loss in Familial GATA2-Deficient MDS Progression.

2026-09-24T00:00:00Z

Published on 24 September 2026 after first appearing as a preprint; matched Single-cell & spatial profiling, GATA2 and STAG2.

24 September 2026.

On OnCo: Single-cell & spatial profiling, GATA2, STAG2

Paper: A rare ATM variant in a Colombian family with chorea-ataxia syndrome: implications for an early diagnosis.

2026-09-24T00:00:00Z

Published on 24 September 2026 after first appearing as a preprint; matched Whole-exome & whole-genome sequencing and ATM.

24 September 2026.

On OnCo: Whole-exome & whole-genome sequencing, ATM

Paper: ASCL1 and OLIG2 Expression Dynamics Control Glial Cell Fate and Regional Diversity in the Dorsal Forebrain.

2026-09-24T00:00:00Z

Published on 24 September 2026 after first appearing as a preprint; matched State, ASCL1 and OLIG2.

24 September 2026.

On OnCo: State, ASCL1, OLIG2

Paper: DesignMaster: A Multi-Conditional Diffusion Framework for Rational PROTAC Design.

2026-09-24T00:00:00Z

Published on 24 September 2026 after first appearing as a preprint; matched PROTACs & molecular glues.

24 September 2026.

On OnCo: PROTACs & molecular glues

Paper: Exploring the feasibility of exercise training during (neo)adjuvant chemotherapy in women with early-stage breast cancer: a pilot study examining immune and metabolic outcomes.

2026-09-24T00:00:00Z

Published on 24 September 2026 after first appearing as a preprint; matched Exercise & lifestyle oncology.

24 September 2026.

On OnCo: Exercise & lifestyle oncology

Paper: Phylogenetic and phylodynamic approaches to understanding the evolution of non-small cell lung cancer using single-cell sequencing.

2026-09-24T00:00:00Z

Published on 24 September 2026 after first appearing as a preprint; matched Nintedanib, Whole-exome & whole-genome sequencing and Single-cell & spatial profiling.

24 September 2026.

On OnCo: Nintedanib, Whole-exome & whole-genome sequencing, Single-cell & spatial profiling

Paper: Population pharmacokinetic analysis of pirtobrutinib, a non-covalent BTK inhibitor, in patients with hematological malignancies from the Phase 1/2 BRUIN study.

2026-09-24T00:00:00Z

Published on 24 September 2026 after first appearing as a preprint; matched BTK, Pirtobrutinib and State.

24 September 2026.

On OnCo: BTK, Pirtobrutinib, State

Paper: Selective dependency of CALR-mutant myeloproliferative neoplasms on TYK2 signaling.

2026-09-24T00:00:00Z

Published on 24 September 2026 after first appearing as a preprint; matched Fedratinib, JAK2 and MPL.

24 September 2026.

On OnCo: Fedratinib, JAK2, MPL, CALR, TYK2, EDNRA

Paper: An expert-level generalist AI for abdominal CT diagnosis.

2026-09-17T00:00:00Z

Published in Science on 17 September 2026; matched the OnCo record for RaDaR.

17 September 2026, Science.

On OnCo: RaDaR

Paper: Anti-B7-H3 ADCs Take Center Stage against SCLC at WCLC.

2026-09-17T00:00:00Z

Published in Cancer Discov on 17 September 2026; matched the OnCo record for YL201.

17 September 2026, Cancer Discov.

On OnCo: YL201

Paper: Levetiracetam therapeutically targets GABAergic synapses in diffuse midline glioma.

2026-09-17T00:00:00Z

Published in Nat Med on 17 September 2026; matched the OnCo record for Diffuse midline glioma, H3 K27-altered.

17 September 2026, Nat Med.

On OnCo: Diffuse midline glioma, H3 K27-altered

Paper: Navigating uncertainties and evidence gaps in adjuvant therapy for premenopausal women with HR+/HER2- breast cancer.

2026-09-17T00:00:00Z

Published in Ann Oncol on 17 September 2026; matched the OnCo record for Goserelin / leuprolide.

17 September 2026, Ann Oncol.

On OnCo: Goserelin / leuprolide

Paper: 18F-CETO in Adrenocortical Carcinoma: First Clinical-Translational Study of An Adrenocortical-targeting PET Tracer.

2026-09-23T00:00:00Z

Published in Endocr Relat Cancer on 23 September 2026; matched the OnCo record for CYP11B1.

23 September 2026, Endocr Relat Cancer.

On OnCo: CYP11B1

Paper: A human cell-free translation screen identifies the NT-2 mycotoxin as a ribosomal inhibitor that binds the peptidyl transferase center.

2026-09-23T00:00:00Z

Published on 23 September 2026 after first appearing as a preprint; matched Elongation factor 2 and State.

23 September 2026.

On OnCo: Elongation factor 2, State

Paper: A Metabolic-Epigenetic Axis of AARS1/IGF2BP3-K280 Lactylation Sustains Endometrial Cancer Stemness and Recurrence.

2026-09-23T00:00:00Z

Published in Adv Sci (Weinh) on 23 September 2026; matched the OnCo record for HMGA2.

23 September 2026, Adv Sci (Weinh).

On OnCo: HMGA2

Paper: A probiotic Bifidobacterium pseudocatenulatum converts hesperidin to bioactive hesperetin and improves metabolic dysfunction in aging mice.

2026-09-23T00:00:00Z

Published in Gut Microbes on 23 September 2026; matched the OnCo record for SIRT1.

23 September 2026, Gut Microbes.

On OnCo: SIRT1

Paper: Cancer-associated mutations in endometriosis reframe a benign disease through molecular oncology.

2026-09-23T00:00:00Z

Published in Mol Oncol on 23 September 2026; matched the OnCo record for ARID1A.

23 September 2026, Mol Oncol.

On OnCo: ARID1A

Paper: Efficient differential expression analysis of large-scale single-cell transcriptomics data using Dreamlet.

2026-09-23T00:00:00Z

Published on 23 September 2026 after first appearing as a preprint; matched Single-cell & spatial profiling.

23 September 2026.

On OnCo: Single-cell & spatial profiling

Paper: Establishment of a cell line-based 3D co-culture model of the endometrium for studying endometrial receptivity.

2026-09-23T00:00:00Z

Published in Am J Physiol Cell Physiol on 23 September 2026; matched the OnCo record for HEY1.

23 September 2026, Am J Physiol Cell Physiol.

On OnCo: HEY1

Paper: Exceptional response to alpelisib in a heavily pretreated patient with metastatic breast cancer carrying a PIK3CA mutation outside SOLAR-1 eligible mutations: a case report.

2026-09-23T00:00:00Z

Published in Acta Oncol on 23 September 2026; found by the roadmap watch for SOLAR-1.

23 September 2026, Acta Oncol.

On OnCo: SOLAR-1, Hormonal therapy roadmap: removing the ovaries → tamoxifen → oral degraders switched by a blood test

Paper: Fast, flexible analysis of differences in cellular composition with crumblr.

2026-09-23T00:00:00Z

Published on 23 September 2026 after first appearing as a preprint; matched Single-cell & spatial profiling.

23 September 2026.

On OnCo: Single-cell & spatial profiling

Paper: FGD1 restrains actomyosin contractility to promote suprabasal junction maturation in stratified keratinocytes.

2026-09-23T00:00:00Z

Published in J Cell Sci on 23 September 2026; matched the OnCo record for FGD1.

23 September 2026, J Cell Sci.

On OnCo: FGD1

Paper: GLG1 in cancer-associated fibroblasts promotes bladder cancer growth while limiting tumor apoptosis.

2026-09-23T00:00:00Z

Published on 23 September 2026 after first appearing as a preprint; matched RNA sequencing & expression profiling, Single-cell & spatial profiling and Ki-67.

23 September 2026.

On OnCo: RNA sequencing & expression profiling, Single-cell & spatial profiling, Ki-67, SMAD2, HSP90B1

Paper: Identification of anoikis-related and cell matrix adhesion genes in the progression of colon adenocarcinoma using bioinformatics analysis.

2026-09-23T00:00:00Z

Published in Comput Methods Biomech Biomed Engin on 23 September 2026; matched the OnCo record for SLC6A2.

23 September 2026, Comput Methods Biomech Biomed Engin.

On OnCo: SLC6A2

Paper: Isolation and Purification-Free Digital Single-Small Extracellular Vesicle Biosensing with Scalable Plasmonic Arrays.

2026-09-23T00:00:00Z

Published on 23 September 2026 after first appearing as a preprint; matched Optical & fluorescence imaging, Liquid biopsy and MIR21.

23 September 2026.

On OnCo: Optical & fluorescence imaging, Liquid biopsy, MIR21

Paper: Multiomics analysis identifies RNASET2 as a potential candidate target associated with lung adenocarcinoma.

2026-09-23T00:00:00Z

Published in J Int Med Res on 23 September 2026; matched the OnCo record for RNASET2.

23 September 2026, J Int Med Res.

On OnCo: RNASET2

Paper: Mutations in untranslated non-coding regions of EGFR, AKT1 & HRAS modulate their expression regulatory networks to facilitate progression of colorectal cancer.

2026-09-23T00:00:00Z

Published in Funct Integr Genomics on 23 September 2026; matched the OnCo record for HRAS.

23 September 2026, Funct Integr Genomics.

On OnCo: HRAS

Paper: nTMS-determined cortical excitability is associated with overall survival in patients with motor-eloquent glioblastoma.

2026-09-23T00:00:00Z

Published on 23 September 2026 after first appearing as a preprint; matched MGMT.

23 September 2026.

On OnCo: MGMT

Paper: Persistent TOP1 cleavage complexes in drug-tolerant cells drive adaptive resistance to EGFR-targeted therapies in lung cancer.

2026-09-23T00:00:00Z

Published on 23 September 2026 after first appearing as a preprint; matched Topotecan, EGFR and Topoisomerase I.

23 September 2026.

On OnCo: Topotecan, EGFR, Topoisomerase I, State

Paper: Structural mechanisms of SAMD9 autoinhibition and pathogenic dysregulation.

2026-09-23T00:00:00Z

Published on 23 September 2026 after first appearing as a preprint; matched SAMD9L and SAMD9.

23 September 2026.

On OnCo: SAMD9L, SAMD9

Paper: The influence of force on the encoding and perception of affective touch.

2026-09-23T00:00:00Z

Published on 23 September 2026 after first appearing as a preprint; matched CD96.

23 September 2026.

On OnCo: CD96

Paper: Urinary collagen type I degradation products as common fibrosis biomarkers in chronic diseases.

2026-09-23T00:00:00Z

Published on 23 September 2026 after first appearing as a preprint; matched Proteomics & phosphoproteomics.

23 September 2026.

On OnCo: Proteomics & phosphoproteomics

Paper: Bridging the Gap: From Molecular Residual Disease to Curative Opportunity: Circulating Tumor DNA-Guided Surveillance After Curative Resection for Stage I to III Colorectal Cancer.

2026-09-16T00:00:00Z

Published in J Clin Oncol on 16 September 2026; matched the OnCo record for Localised anal squamous cell carcinoma.

16 September 2026, J Clin Oncol.

On OnCo: Localised anal squamous cell carcinoma

Paper: Chemotherapy-free phase 1/2 trial of HRS-4642 plus adebrelimab in previously treated metastatic KRAS G12D-mutant pancreatic cancer.

2026-09-16T00:00:00Z

Published in Cancer Cell on 16 September 2026; matched the OnCo record for Adebrelimab.

16 September 2026, Cancer Cell.

On OnCo: Adebrelimab

Paper: Erratum: Biomarker-Stratified Phase II Trial of Trastuzumab Rezetecan in Advanced Salivary Gland Carcinoma Across Cohorts With High and Low Human Epidermal Growth Factor Receptor 2 Expression.

2026-09-16T00:00:00Z

Published in J Clin Oncol on 16 September 2026; matched the OnCo record for Trastuzumab rezetecan.

16 September 2026, J Clin Oncol.

On OnCo: Trastuzumab rezetecan

Paper: Identification of broadly tumour-reactive γδ TCRs from multiple myeloma.

2026-09-16T00:00:00Z

Published in Nature on 16 September 2026; matched the OnCo record for HLA-C.

16 September 2026, Nature.

On OnCo: HLA-C

Paper: Mitochondrial fission factor senses and governs ferroptosis.

2026-09-16T00:00:00Z

Published in Nature on 16 September 2026; matched the OnCo record for PRKCB.

16 September 2026, Nature.

On OnCo: PRKCB

Approval: FDA grants accelerated approval to sevabertinib for locally advanced or metastatic non-squamous non-small cell lung cancer

2026-09-09T00:00:00Z

On September 9, 2026, the Food and Drug Administration granted accelerated approval to sevabertinib (Hyrnuo, Bayer Healthcare Pharmaceuticals Inc.), a kinase inhibitor, for adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase domain (TKD) activating mutations, as detected by an FDA-authorized test.

9 September 2026, FDA.

On OnCo: Sevabertinib, Lung cancer, Squamous cell carcinoma of the lung, Non-small-cell lung cancer, HER2-mutant non-small-cell lung cancer, HER2

Paper: A prostate cancer-specific super-enhancer at 1q42.3 regulates the CAPN2 and KRT19.

2026-09-22T00:00:00Z

Published in J Biol Chem on 22 September 2026; matched the OnCo record for ETV5.

22 September 2026, J Biol Chem.

On OnCo: ETV5

Paper: A USP28-BRD4 axis contributes to the acceleration of breast cancer growth by hyperglycemia.

2026-09-22T00:00:00Z

Published in Cell Rep on 22 September 2026; matched the OnCo record for USP28.

22 September 2026, Cell Rep.

On OnCo: USP28

Paper: Activation-induced cytidine deaminase sustains glycolytic flux through MYST1 acetyltransferase-dependent lactylation in hepatocellular carcinoma.

2026-09-22T00:00:00Z

Published in J Biol Chem on 22 September 2026; matched the OnCo record for CDA.

22 September 2026, J Biol Chem.

On OnCo: CDA

Paper: Application of aiAtlas Version 1.2 to Simulate Variant Gene Function Restoration and Rescue Thresholds in Rare Diseases: Validation Case Study.

2026-09-22T00:00:00Z

Published in JMIR Bioinform Biotechnol on 22 September 2026; matched the OnCo record for ERCC2.

22 September 2026, JMIR Bioinform Biotechnol.

On OnCo: ERCC2

Paper: Assessment of combined antiviral drug treatment against selected α-, β-, and γ-herpesviruses.

2026-09-22T00:00:00Z

Published on 22 September 2026 after first appearing as a preprint; matched Small-molecule kinase inhibitors, CDK4/6 inhibitors and Abemaciclib.

22 September 2026.

On OnCo: Small-molecule kinase inhibitors, CDK4/6 inhibitors, Abemaciclib

Paper: BK_Ca channel deletion modulates the DNA damage response to electron ultra-high dose rate irradiation in glioblastoma cells.

2026-09-22T00:00:00Z

Published in J Neurooncol on 22 September 2026; matched the OnCo record for TP53BP1.

22 September 2026, J Neurooncol.

On OnCo: TP53BP1

Paper: Breaking the deadlock of metallo-β-lactamases: evidence and prospects for Aztreonam/Avibactam.

2026-09-22T00:00:00Z

Published in Emerg Microbes Infect on 22 September 2026; matched the OnCo record for ATM.

22 September 2026, Emerg Microbes Infect.

On OnCo: ATM

Paper: Calcitriol alleviates ARID2-deficient gastric cancer metastasis via inhibition of the Wnt/β-catenin signaling pathway.

2026-09-22T00:00:00Z

Published in Transl Oncol on 22 September 2026; matched the OnCo record for ARID2.

22 September 2026, Transl Oncol.

On OnCo: ARID2

Paper: Characterizing intra- and intertumor heterogeneity in ovarian high-grade serous carcinoma subtypes using single-cell and spatial transcriptomics.

2026-09-22T00:00:00Z

Published on 22 September 2026 after first appearing as a preprint; matched RNA sequencing & expression profiling, Single-cell & spatial profiling and Spatial transcriptomics.

22 September 2026.

On OnCo: RNA sequencing & expression profiling, Single-cell & spatial profiling, Spatial transcriptomics

Paper: Cost and cost-effectiveness of alternative screening and diagnostic pathways for achieving hepatitis C elimination in the country of Georgia.

2026-09-22T00:00:00Z

Published on 22 September 2026 after first appearing as a preprint; matched Abiraterone acetate, Docetaxel and Leucovorin.

22 September 2026.

On OnCo: Abiraterone acetate, Docetaxel, Leucovorin

Paper: Development of an isavuconazole physiologically-based pharmacokinetic model for adult and pediatric populations.

2026-09-22T00:00:00Z

Published on 22 September 2026 after first appearing as a preprint; matched Azacitidine, Decitabine + cedazuridine and MAX.

22 September 2026.

On OnCo: Azacitidine, Decitabine + cedazuridine, MAX

Paper: Donor and recipient immune programs underlying delayed graft function in kidney transplantation revealed by temporal single-cell profiling.

2026-09-22T00:00:00Z

Published in Kidney Int on 22 September 2026; matched the OnCo record for AREG.

22 September 2026, Kidney Int.

On OnCo: AREG

Paper: Dynamic remodeling of the transcriptional landscape drives Merkel cell specification and mechanosensory differentiation.

2026-09-22T00:00:00Z

Published in Proc Natl Acad Sci U S A on 22 September 2026; matched the OnCo record for TUBB3.

22 September 2026, Proc Natl Acad Sci U S A.

On OnCo: TUBB3

Paper: Evaluation of the image quality index with MRI motion artifacts on tumor segmentation using deep learning.

2026-09-22T00:00:00Z

Published on 22 September 2026 after first appearing as a preprint; matched MRI.

22 September 2026.

On OnCo: MRI

Paper: Fine-tuning the lysine-arginine duet: a dietary approach to suppress tumor growth.

2026-09-22T00:00:00Z

Published in Mol Biomed on 22 September 2026; matched the OnCo record for HBB.

22 September 2026, Mol Biomed.

On OnCo: HBB, RPS29

Paper: From genomic instability to epigenetic regulation: the role of DNA repair gene variants and non-coding RNAs in colorectal carcinogenesis.

2026-09-22T00:00:00Z

Published in Nucleosides Nucleotides Nucleic Acids on 22 September 2026; matched the OnCo record for ERCC1.

22 September 2026, Nucleosides Nucleotides Nucleic Acids.

On OnCo: ERCC1, MUTYH

Paper: Genetic evaluation of encorafenib-associated kinases RAF1 and MAPK8 in pancreatic cancer: Exploratory mediation by circulating immune traits.

2026-09-22T00:00:00Z

Published in Transl Oncol on 22 September 2026; matched the OnCo record for MAPK8.

22 September 2026, Transl Oncol.

On OnCo: MAPK8

Paper: IL-15 trans-presentation at the innate-adaptive interface: mechanisms and translation in cancer immunotherapy.

2026-09-22T00:00:00Z

Published in Oncoimmunology on 22 September 2026; matched the OnCo record for IL2RB.

22 September 2026, Oncoimmunology.

On OnCo: IL2RB, IL2RG, TNFRSF10B

Paper: Integrated multi-omics identifies lineage-dependent myeloid cells recruitment and the APP-CD74 axis as an immunoregulatory target in pediatric high-grade glioma.

2026-09-22T00:00:00Z

Published on 22 September 2026 after first appearing as a preprint; matched RNA sequencing & expression profiling, Single-cell & spatial profiling and State.

22 September 2026.

On OnCo: RNA sequencing & expression profiling, Single-cell & spatial profiling, State, CD74

Paper: Integrative Genetic Analyses Identify Mitochondrial-Related Genes Associated With Female Reproductive Disorders.

2026-09-22T00:00:00Z

Published in Mol Cell Endocrinol on 22 September 2026; matched the OnCo record for ALDH2.

22 September 2026, Mol Cell Endocrinol.

On OnCo: ALDH2

Paper: Integrative profiling of multi-modal plasma cfRNA signatures enables detection and prognostic risk stratification in breast cancer.

2026-09-22T00:00:00Z

Published in Genomics on 22 September 2026; matched the OnCo record for DLST.

22 September 2026, Genomics.

On OnCo: DLST

Paper: Ki-67 expression and rates of pathologic complete response in T1cN0M0 triple-negative breast cancer: a national cancer database analysis.

2026-09-22T00:00:00Z

Published in Breast Cancer Res Treat on 22 September 2026; matched the OnCo record for Invasive lobular carcinoma of the breast.

22 September 2026, Breast Cancer Res Treat.

On OnCo: Invasive lobular carcinoma of the breast, Ki-67

Paper: Low-Grade Salivary Myoepithelial Carcinoma of the Upper Lip Harboring a Novel CARMN/miR143HG::PLAG1 Fusion.

2026-09-22T00:00:00Z

Published in Head Neck Pathol on 22 September 2026; matched the OnCo record for PLAG1.

22 September 2026, Head Neck Pathol.

On OnCo: PLAG1

Paper: Midazolam suppresses glioma progression by attenuating neuronal activity and downregulating IGF1 signaling.

2026-09-22T00:00:00Z

Published on 22 September 2026 after first appearing as a preprint; matched RNA sequencing & expression profiling, AKT and Ki-67.

22 September 2026.

On OnCo: RNA sequencing & expression profiling, AKT, Ki-67

Paper: miR-324-5p acts as an independent prognostic biomarker and inhibits pediatric medulloblastoma progression by targeting HOXA9.

2026-09-22T00:00:00Z

Published in Nucleosides Nucleotides Nucleic Acids on 22 September 2026; matched the OnCo record for HOXA9.

22 September 2026, Nucleosides Nucleotides Nucleic Acids.

On OnCo: HOXA9

Paper: Modeling Liver Cancer Molecular and Histological Features by CRISPR Editing of Porcine Hepatocytes.

2026-09-22T00:00:00Z

Published in JHEP Rep on 22 September 2026; matched the OnCo record for AXIN1.

22 September 2026, JHEP Rep.

On OnCo: AXIN1

Paper: Modular mRNA cocktail enables synergistic activation of antigen-specific T cells for cancer immunotherapy.

2026-09-22T00:00:00Z

Published in Oncoimmunology on 22 September 2026; matched the OnCo record for CD80.

22 September 2026, Oncoimmunology.

On OnCo: CD80, CTAG1B, HLA-A

Paper: Molecular underpinnings of metastatic small renal masses.

2026-09-22T00:00:00Z

Published in JCI Insight on 22 September 2026; matched the OnCo record for SRMS.

22 September 2026, JCI Insight.

On OnCo: SRMS

Paper: Obesity associated elevated leptin might contribute to paclitaxel resistance via PLCB1/IP3R1 axis in head and neck cancers.

2026-09-22T00:00:00Z

Published in Biochim Biophys Acta Mol Basis Dis on 22 September 2026; matched the OnCo record for ITPR1.

22 September 2026, Biochim Biophys Acta Mol Basis Dis.

On OnCo: ITPR1

Paper: Peripheral biomarkers of anxiety in autism and attention deficit/hyperactivity disorder.

2026-09-22T00:00:00Z

Published in Dev Neurosci on 22 September 2026; matched the OnCo record for CX3CL1.

22 September 2026, Dev Neurosci.

On OnCo: CX3CL1

Paper: POLE2 of tumor cells promotes OPN secretion based on PCLAF to drive M2 macrophage polarization in clear cell renal cell carcinoma.

2026-09-22T00:00:00Z

Published in Cancer Gene Ther on 22 September 2026; matched the OnCo record for NFATC2.

22 September 2026, Cancer Gene Ther.

On OnCo: NFATC2, POLE2

Paper: Predictive molecular signatures for successful tapering of canakinumab in systemic juvenile idiopathic arthritis.

2026-09-22T00:00:00Z

Published in Ann Rheum Dis on 22 September 2026; matched the OnCo record for BCL6.

22 September 2026, Ann Rheum Dis.

On OnCo: BCL6, MAPK1, TNFAIP3

Paper: PRMT1-SFPQ regulates intron retention to control matrix gene expression during craniofacial development.

2026-09-22T00:00:00Z

Published in Elife on 22 September 2026; matched the OnCo record for SFPQ.

22 September 2026, Elife.

On OnCo: SFPQ

Paper: Proteogenomic Analysis of HDAC4 and HDAC5 in Uveal Melanoma.

2026-09-22T00:00:00Z

Published in Mol Med on 22 September 2026; matched the OnCo record for HDAC5.

22 September 2026, Mol Med.

On OnCo: HDAC5

Paper: Real-world data from patients treated with chemotherapy for biliary tract cancer: insights from a prognostic model. ^☆.

2026-09-22T00:00:00Z

Published in JHEP Rep on 22 September 2026; matched the OnCo record for PSEN2.

22 September 2026, JHEP Rep.

On OnCo: PSEN2

Paper: Reproductive factors and the expression of stromal markers in benign breast biopsy samples.

2026-09-22T00:00:00Z

Published in Br J Cancer on 22 September 2026; matched the OnCo record for TNC.

22 September 2026, Br J Cancer.

On OnCo: TNC

Paper: Right ventricular pressure overload disturbs T-tubule maturation via MEF2D's transcriptional regulation of BIN1.

2026-09-22T00:00:00Z

Published in JCI Insight on 22 September 2026; matched the OnCo record for MEF2D.

22 September 2026, JCI Insight.

On OnCo: MEF2D

Paper: Role of the miR-1298/Bone Morphogenetic Protein 7 Axis in Colorectal Cancer.

2026-09-22T00:00:00Z

Published in J Vis Exp on 22 September 2026; matched the OnCo record for BMP7.

22 September 2026, J Vis Exp.

On OnCo: BMP7

Paper: SDCBP competes with CBL to stabilize PES1 and promote c-Myc translation in ESCC tumorigenesis.

2026-09-22T00:00:00Z

Published in Cell Rep on 22 September 2026; matched the OnCo record for CBL.

22 September 2026, Cell Rep.

On OnCo: CBL, SDCBP

Paper: Semi-automated erythema quantification in infantile haemangioma receiving propranolol: a pilot feasibility study.

2026-09-22T00:00:00Z

Published on 22 September 2026 after first appearing as a preprint; matched Propranolol.

22 September 2026.

On OnCo: Propranolol

Paper: Spatiotemporally controlled degradation of CDK6 via light-triggered ROS generation: uncovering the proximity effect-mediated dual target depletion.

2026-09-22T00:00:00Z

Published in Org Biomol Chem on 22 September 2026; matched the OnCo record for CCND3.

22 September 2026, Org Biomol Chem.

On OnCo: CCND3

Paper: Structural and functional divergence of cancer hotspot mutations in CREBBP.

2026-09-22T00:00:00Z

Published in Proc Natl Acad Sci U S A on 22 September 2026; matched the OnCo record for CREBBP.

22 September 2026, Proc Natl Acad Sci U S A.

On OnCo: CREBBP

Paper: Structural organization of TAM receptor ectodomains.

2026-09-22T00:00:00Z

Published in Biochem J on 22 September 2026; matched the OnCo record for MERTK.

22 September 2026, Biochem J.

On OnCo: MERTK

Paper: Successful management of paediatric chronic SIAD with oral urea: report of two cases.

2026-09-22T00:00:00Z

Published in J Pediatr Endocrinol Metab on 22 September 2026; matched the OnCo record for Paediatric low-grade glioma.

22 September 2026, J Pediatr Endocrinol Metab.

On OnCo: Paediatric low-grade glioma

Paper: Targeting PPP1R14B overcomes immunotherapy resistance in prostate cancer by restoring CD8⁺ T-cell infiltration via the Nrf2/CX3CL1 axis.

2026-09-22T00:00:00Z

Published in J Pathol on 22 September 2026; matched the OnCo record for CX3CL1.

22 September 2026, J Pathol.

On OnCo: CX3CL1

Paper: The Drosophila FET ortholog Cabeza is an essential cofactor for ETV4-mediated activation of GGAA microsatellite neoenhancers.

2026-09-22T00:00:00Z

Published in G3 (Bethesda) on 22 September 2026; matched the OnCo record for ETV4.

22 September 2026, G3 (Bethesda).

On OnCo: ETV4, ETV6

Paper: The pathological significance of DNA damage-inducible transcript 3 immunohistochemistry in the diagnosis of myxoid liposarcoma.

2026-09-22T00:00:00Z

Published in Rev Esp Patol on 22 September 2026; matched the OnCo record for DDIT3.

22 September 2026, Rev Esp Patol.

On OnCo: DDIT3

Paper: Tumor-induced osteomalacia caused by fibroblast growth factor 23 excess : Delayed diagnosis resulting from overlooked hypophosphatemia-A case report.

2026-09-22T00:00:00Z

Published in Wien Klin Wochenschr on 22 September 2026; matched the OnCo record for FGF23.

22 September 2026, Wien Klin Wochenschr.

On OnCo: FGF23

Paper: Unexpected neonatal ABO discrepancy revealing ABO*cisAB.05 during routine cord blood testing.

2026-09-22T00:00:00Z

Published in Transfusion on 22 September 2026; matched the OnCo record for ABO.

22 September 2026, Transfusion.

On OnCo: ABO

Paper: Uterine Tumor Resembling Ovarian Sex Cord Tumor With GREB1::NCOA2 Fusion and Neuroendocrine Marker Expression: A Case Report and Literature Review.

2026-09-22T00:00:00Z

Published in Int J Surg Pathol on 22 September 2026; matched the OnCo record for NCOA2.

22 September 2026, Int J Surg Pathol.

On OnCo: NCOA2

Paper: VGLL4 enhances PDK4 transcription and promotes metabolic dysfunction-associated fatty liver disease.

2026-09-22T00:00:00Z

Published in EMBO Rep on 22 September 2026; matched the OnCo record for CEBPA.

22 September 2026, EMBO Rep.

On OnCo: CEBPA

Paper: Author Correction: Erythropoietin receptor on cDC1s dictates immune tolerance.

2026-09-15T00:00:00Z

Published in Nature on 15 September 2026; matched the OnCo record for Erythropoietin receptor.

15 September 2026, Nature.

On OnCo: Erythropoietin receptor

Paper: Circulating Tumor DNA Profiling Defines Risk Classification in Patients With Ewing Sarcoma: A Report From the Children's Oncology Group and the LEOPARD Study.

2026-09-15T00:00:00Z

Published in J Clin Oncol on 15 September 2026; matched the OnCo record for STAG2.

15 September 2026, J Clin Oncol.

On OnCo: STAG2

Paper: Oral KRAS G12D inhibitor GFH375 for previously treated advanced solid tumors with KRASG12D mutations: a phase 1 trial.

2026-09-15T00:00:00Z

Published in Nat Med on 15 September 2026; matched the OnCo record for GFH375.

15 September 2026, Nat Med.

On OnCo: GFH375

Paper: Targeting BLVRB Overcomes Immunosuppression and Potentiates Immunotherapy in Monocytic Acute Myeloid Leukemia.

2026-09-15T00:00:00Z

Published in Cancer Discov on 15 September 2026; matched the OnCo record for MAFB.

15 September 2026, Cancer Discov.

On OnCo: MAFB

Preprint: A druggable chromatin vulnerability in suppressive neutrophils restores antitumor immunity

2026-09-28T00:00:00Z

Posted on bioRxiv on 28 September 2026; not peer reviewed; matched Immune checkpoint inhibitors, PD-1 and State.

28 September 2026, bioRxiv.

On OnCo: Immune checkpoint inhibitors, PD-1, State

Preprint: A Multi-Agent Framework for Explainable Brain Tumour Instance Segmentation and Clinical Report Generation Using ASIO-Optimised YOLO Architectures

2026-09-28T00:00:00Z

Posted on Research Square on 28 September 2026; not peer reviewed; matched MRI, AI in radiology and State.

28 September 2026, Research Square.

On OnCo: MRI, AI in radiology, State

Preprint: A Physics-Informed Neural Network Surrogate for Patient-Specific Hepatic Arterial Hemodynamics in Yttrium-90 Radioembolization: Network Architecture, Boundary-Condition Enforcement, and Data Efficiency

2026-09-28T00:00:00Z

Posted on bioRxiv on 28 September 2026; not peer reviewed; matched State.

28 September 2026, bioRxiv.

On OnCo: State

Preprint: A serum thyroid hormone metabolite test for molecular diagnostic evaluation of thyroid nodules

2026-09-28T00:00:00Z

Posted on medRxiv on 28 September 2026; not peer reviewed; matched ELL.

28 September 2026, medRxiv.

On OnCo: ELL

Preprint: Awareness and Barriers to Cervical Cancer Screening and HPV Vaccination in Rural Ebonyi State: A Multicenter Cross-sectional Study

2026-09-28T00:00:00Z

Posted on Research Square on 28 September 2026; not peer reviewed; matched HPV & HBV vaccination, Chemoprevention & risk-reducing surgery and State.

28 September 2026, Research Square.

On OnCo: HPV & HBV vaccination, Chemoprevention & risk-reducing surgery, State

Preprint: BiomiX 3.0: A user-friendly platform for democratized multi-omics integration with graph-based learning.

2026-09-28T00:00:00Z

Posted on bioRxiv on 28 September 2026; not peer reviewed; matched State and CCDC6.

28 September 2026, bioRxiv.

On OnCo: State, CCDC6

Preprint: Boric Acid Combined With Doxorubicin Demonstrates Antitumoral And Anti İnflammatory Effects in An Experimental Triple Negative Breast Cancer Model

2026-09-28T00:00:00Z

Posted on Research Square on 28 September 2026; not peer reviewed; matched Azacitidine, Decitabine + cedazuridine and Doxorubicin.

28 September 2026, Research Square.

On OnCo: Azacitidine, Decitabine + cedazuridine, Doxorubicin, Ki-67

Preprint: CAR T cell targeting of inflammatory myeloid progenitors in the bone marrow remodels border-associated macrophages and reverses cognitive aging

2026-09-28T00:00:00Z

Posted on bioRxiv on 28 September 2026; not peer reviewed; matched CAR-T cell therapy.

28 September 2026, bioRxiv.

On OnCo: CAR-T cell therapy

Preprint: Causal relationship between liver fat reduction and clinical outcomes in human genetic studies and randomized clinical trials of metabolic-dysfunction associated steatohepatitis

2026-09-28T00:00:00Z

Posted on medRxiv on 28 September 2026; not peer reviewed; matched MRI and SET.

28 September 2026, medRxiv.

On OnCo: MRI, SET

Preprint: ClusterSyn: Cell-Line-Specific Topology-Aware Drug-Combination Response Prediction on the O'Neil Dataset

2026-09-28T00:00:00Z

Posted on Research Square on 28 September 2026; not peer reviewed; matched Fluorouracil.

28 September 2026, Research Square.

On OnCo: Fluorouracil

Preprint: Combined Loss of VHL and TSC1 Drives Clear Cell Renal Cell Carcinoma with Metabolic and Redox Reprogramming that Creates an NRF2 Dependency

2026-09-28T00:00:00Z

Posted on bioRxiv on 28 September 2026; not peer reviewed; matched TSC1, VHL and NFE2L2.

28 September 2026, bioRxiv.

On OnCo: TSC1, VHL, NFE2L2

Preprint: Conjunctive Targeting Links Drug Synergy to Emergent Proteome Structural States

2026-09-28T00:00:00Z

Posted on bioRxiv on 28 September 2026; not peer reviewed; matched Proteomics & phosphoproteomics, Ruxolitinib and MEK1/2.

28 September 2026, bioRxiv.

On OnCo: Proteomics & phosphoproteomics, Ruxolitinib, MEK1/2, SHP2, BRD4, PIK3R1

Preprint: Context-dependent regulation of malignant phenotypes by PCK1 in oral squamous cell carcinoma and its association with lactate- related transcriptomic features

2026-09-28T00:00:00Z

Posted on Research Square on 28 September 2026; not peer reviewed; matched Azacitidine, Decitabine + cedazuridine and AKT.

28 September 2026, Research Square.

On OnCo: Azacitidine, Decitabine + cedazuridine, AKT, State, Ki-67, ABCB1

Preprint: ctDNA Release Heterogeneity in Luminal Breast Cancer Revealed by Single-Cell Multi-Omics Spatial Analysis

2026-09-28T00:00:00Z

Posted on bioRxiv on 28 September 2026; not peer reviewed; matched Single-cell & spatial profiling, Liquid biopsy and Spatial transcriptomics.

28 September 2026, bioRxiv.

On OnCo: Single-cell & spatial profiling, Liquid biopsy, Spatial transcriptomics, HER2, PIK3CA / PI3K-alpha, Estrogen receptor

Preprint: Deciphering the association of spatial landscapes of DCIS with recurrence as invasive breast cancer

2026-09-28T00:00:00Z

Posted on bioRxiv on 28 September 2026; not peer reviewed; matched CD44 and Galectin-9.

28 September 2026, bioRxiv.

On OnCo: CD44, Galectin-9

Preprint: Development and Internal Validation of a Lifestyle-Based Risk Prediction Model for 10-Year Incident Kidney Cancer in the 45 and Up Study

2026-09-28T00:00:00Z

Posted on Research Square on 28 September 2026; not peer reviewed; matched SET.

28 September 2026, Research Square.

On OnCo: SET

Preprint: Disruption of the ARID1A-containing SWI/SNF complex reprograms tumor-associated macrophages and enhances immunotherapy response

2026-09-28T00:00:00Z

Posted on bioRxiv on 28 September 2026; not peer reviewed; matched Single-cell & spatial profiling, ARID1A and CD86.

28 September 2026, bioRxiv.

On OnCo: Single-cell & spatial profiling, ARID1A, CD86

Preprint: DS5: An Open-Source Framework for Standardized High-Throughput Drug Screening Data Storage, Analysis, and Drug Prioritization

2026-09-28T00:00:00Z

Posted on bioRxiv on 28 September 2026; not peer reviewed; matched CCDC6.

28 September 2026, bioRxiv.

On OnCo: CCDC6

Preprint: Enhancing the hyaline cartilage regenerative potential of induced pluripotent stem cell-derived chondrocyte cell sheets

2026-09-28T00:00:00Z

Posted on bioRxiv on 28 September 2026; not peer reviewed; matched GD2, CCDC6 and TGFB1.

28 September 2026, bioRxiv.

On OnCo: GD2, CCDC6, TGFB1, SOX9, COL2A1

Preprint: Fibers and Glasses are Competing Material States in FUS Protein Condensation

2026-09-28T00:00:00Z

Posted on bioRxiv on 28 September 2026; not peer reviewed; matched State and FUS.

28 September 2026, bioRxiv.

On OnCo: State, FUS

Preprint: Fluorosphere-Assisted Nano-Biosensor for Detection of Circulating microRNAs in Non-Small Cell Lung Cancer

2026-09-28T00:00:00Z

Posted on bioRxiv on 28 September 2026; not peer reviewed; matched Nintedanib.

28 September 2026, bioRxiv.

On OnCo: Nintedanib

Preprint: Giant Metaplastic Breast Carcinoma with Extensive Osseous Differentiation Requiring Emergency Mastectomy: A Case Report

2026-09-28T00:00:00Z

Posted on Research Square on 28 September 2026; not peer reviewed; matched CCDC6.

28 September 2026, Research Square.

On OnCo: CCDC6

Preprint: Glabellar flap reconstruction following wide local excision of nasal basal cell carcinoma

2026-09-28T00:00:00Z

Posted on Research Square on 28 September 2026; not peer reviewed; matched CCDC6.

28 September 2026, Research Square.

On OnCo: CCDC6

Preprint: Highly inducible transcription is impaired in cells lacking Cyclin T1 (CycT1) of the positive transcription factor b (P-TEFb).

2026-09-28T00:00:00Z

Posted on bioRxiv on 28 September 2026; not peer reviewed; matched State, NR4A3 and CDK9.

28 September 2026, bioRxiv.

On OnCo: State, NR4A3, CDK9, CCNT1, RELA

Preprint: How Does Health Literacy Shape Preventive Healthcare Decisions on Human Papillomavirus Vaccination?

2026-09-28T00:00:00Z

Posted on Preprints.org on 28 September 2026; not peer reviewed; matched HPV & HBV vaccination.

28 September 2026, Preprints.org.

On OnCo: HPV & HBV vaccination

Preprint: Immune checkpoint inhibitor-associated TTP: can patients be rechallenged with immunotherapy?

2026-09-28T00:00:00Z

Posted on Research Square on 28 September 2026; not peer reviewed; matched Rituximab, Immune checkpoint inhibitors and Nivolumab.

28 September 2026, Research Square.

On OnCo: Rituximab, Immune checkpoint inhibitors, Nivolumab, Ipilimumab

Preprint: Incidence and Procedural Risk Factors for Symptomatic Cholecystitis After Yttrium-90 Transarterial Radioembolization: A Systematic Review and Meta-analysis

2026-09-28T00:00:00Z

Posted on Research Square on 28 September 2026; not peer reviewed; matched MET.

28 September 2026, Research Square.

On OnCo: MET

Preprint: Integrated immunopeptidomics and transcriptomics reveal a cancer-restricted non-canonical HLA class I ligandome in medulloblastoma

2026-09-28T00:00:00Z

Posted on bioRxiv on 28 September 2026; not peer reviewed; matched HLA-A.

28 September 2026, bioRxiv.

On OnCo: HLA-A

Preprint: Integrated RNA-based functional characterization facilitates reclassification of BRCA1/2 variants of uncertain significance in a clinical cancer cohort

2026-09-28T00:00:00Z

Posted on Research Square on 28 September 2026; not peer reviewed; matched RNA sequencing & expression profiling, BRCA1 / BRCA2 and SEM1.

28 September 2026, Research Square.

On OnCo: RNA sequencing & expression profiling, BRCA1 / BRCA2, SEM1, CCDC6

Preprint: Integration of Multidimensional Genetic and Single- Cell Analyses to Identify Potential Drug Targets and a Clinical Risk Prediction Model for Cervical Cancer

2026-09-28T00:00:00Z

Posted on Research Square on 28 September 2026; not peer reviewed; matched RNA sequencing & expression profiling, Single-cell & spatial profiling and PDCD1LG2.

28 September 2026, Research Square.

On OnCo: RNA sequencing & expression profiling, Single-cell & spatial profiling, PDCD1LG2, MMP1

Preprint: Integrator governs NF-κB dwell time on chromatin to drive inflammatory transcription

2026-09-28T00:00:00Z

Posted on bioRxiv on 28 September 2026; not peer reviewed; matched State and RELA.

28 September 2026, bioRxiv.

On OnCo: State, RELA

Preprint: m ⁶ A-Driven Intratumoral Cholesterol Biosynthesis Fuels Castration-Resistant Prostate Cancer Progression

2026-09-28T00:00:00Z

Posted on bioRxiv on 28 September 2026; not peer reviewed; matched Androgen receptor.

28 September 2026, bioRxiv.

On OnCo: Androgen receptor

Preprint: Machine Learning Model for Predicting Operative Duration in Transsphenoidal Neuroendoscopic Pituitary Adenomectomy

2026-09-28T00:00:00Z

Posted on Research Square on 28 September 2026; not peer reviewed; matched SET.

28 September 2026, Research Square.

On OnCo: SET

Preprint: Metabolic profiling of licensed mesenchymal stromal cells reveals a disconnect between glycolytic fitness and immunomodulatory responsiveness

2026-09-28T00:00:00Z

Posted on bioRxiv on 28 September 2026; not peer reviewed; matched IDO1 and CTSS.

28 September 2026, bioRxiv.

On OnCo: IDO1, CTSS

Preprint: Multimodal Artificial Intelligence Model Integrating Multiparametric MRI Features and PSA for Differentiating Benign and Malignant Prostate Nodules

2026-09-28T00:00:00Z

Posted on Research Square on 28 September 2026; not peer reviewed; matched MRI, Radiomics and KLK3.

28 September 2026, Research Square.

On OnCo: MRI, Radiomics, KLK3, SET

Preprint: Mutation Order and Selection Shape Intratumor Heterogeneity in Tumor Evolution

2026-09-28T00:00:00Z

Posted on bioRxiv on 28 September 2026; not peer reviewed; matched SET.

28 September 2026, bioRxiv.

On OnCo: SET

Preprint: Nanoparticle Albumin-Bound Paclitaxel Targets Pulmonary Neutrophils

2026-09-28T00:00:00Z

Posted on bioRxiv on 28 September 2026; not peer reviewed; matched Paclitaxel / nab-paclitaxel and Nab-paclitaxel.

28 September 2026, bioRxiv.

On OnCo: Paclitaxel / nab-paclitaxel, Nab-paclitaxel

Preprint: Nucleosome-scale p53-hormone receptor grammar distributed by Alu elements

2026-09-28T00:00:00Z

Posted on bioRxiv on 28 September 2026; not peer reviewed; matched Estrogen receptor and Androgen receptor.

28 September 2026, bioRxiv.

On OnCo: Estrogen receptor, Androgen receptor

Preprint: Palmitate-activated IRE1-XBP1 signaling limits DNA damage and is associated with H2A.X-linked DNA damage response transcripts in triple-negative breast cancer cells

2026-09-28T00:00:00Z

Posted on bioRxiv on 28 September 2026; not peer reviewed; matched BRCA1 / BRCA2 and Etoposide.

28 September 2026, bioRxiv.

On OnCo: BRCA1 / BRCA2, Etoposide

Preprint: PGG Enhances Olaparib Efficacy via cGAS-STING Signaling and Sensitizes Triple-Negative Breast Cancer to PD- L1 Blockade

2026-09-28T00:00:00Z

Posted on bioRxiv on 28 September 2026; not peer reviewed; matched HRD & BRCA testing, PARP inhibitors and Synthetic lethality approaches.

28 September 2026, bioRxiv.

On OnCo: HRD & BRCA testing, PARP inhibitors, Synthetic lethality approaches, Immune checkpoint inhibitors, STING & innate immune agonists, PD-L1

Paper: Citrus reticulata Essential Oil as a Bioactive Food Ingredient: Composition Variability, Extraction, Functional Bioactivities, and Cross-Study Quantitative Analysis.

2026-09-21T00:00:00Z

Published in Food Sci Nutr on 21 September 2026; found by the roadmap watch for CROSS.

21 September 2026, Food Sci Nutr.

On OnCo: CROSS, Chemotherapy roadmap: mustard gas → curative combinations → the warhead inside smarter drugs, Radiotherapy roadmap: X-rays → shaped beams → fewer fractions, particles and FLASH

Paper: A Phase I/II Trial of Anti-CD22/CD19 CAR-T Cell Therapy, CART2219.1, in Adult and Pediatric Relapsed/Refractory B-ALL.

2026-09-21T00:00:00Z

Published in Blood Cancer Discov on 21 September 2026; matched the OnCo record for Acute lymphoblastic leukaemia.

21 September 2026, Blood Cancer Discov.

On OnCo: Acute lymphoblastic leukaemia, BACH2, CD22, LEF1

Paper: An Allometric Approach to Fine-Mapping Subcortical Volume Alterations in RASopathies.

2026-09-21T00:00:00Z

Published in eNeuro on 21 September 2026; matched the OnCo record for SOS1.

21 September 2026, eNeuro.

On OnCo: SOS1

Paper: Androgens Drive SOX9 Upregulation in Injured Proximal Tubular Cells.

2026-09-21T00:00:00Z

Published in Kidney Int on 21 September 2026; matched the OnCo record for SOX9.

21 September 2026, Kidney Int.

On OnCo: SOX9, Cisplatin, Platinum agents, Androgen receptor

Paper: Assessment of Lectin Staining Biomarkers for GNE Myopathy Gene Therapy.

2026-09-21T00:00:00Z

Published in Muscle Nerve on 21 September 2026; matched the OnCo record for Small intestine cancer.

21 September 2026, Muscle Nerve.

On OnCo: Small intestine cancer

Paper: BCLXL blockade rewires cell fate to overcome PARP inhibitor resistance in ovarian cancer.

2026-09-21T00:00:00Z

Published in Signal Transduct Target Ther on 21 September 2026; matched the OnCo record for BIM.

21 September 2026, Signal Transduct Target Ther.

On OnCo: BIM

Paper: Carmofur inhibits ovarian cancer cell proliferation, migration, and invasion via disrupting the YAP-1/TEAD pathway: in vitro and in silico approaches.

2026-09-21T00:00:00Z

Published in 3 Biotech on 21 September 2026; matched the OnCo record for YAP1.

21 September 2026, 3 Biotech.

On OnCo: YAP1

Paper: CD36 links fatty acid metabolism to tumor immune microenvironment remodeling in breast cancer.

2026-09-21T00:00:00Z

Published in Transl Oncol on 21 September 2026; matched the OnCo record for FGA.

21 September 2026, Transl Oncol.

On OnCo: FGA

Paper: Chemotherapy-Free Polatuzumab Vedotin and Rituximab (Pola-R) for Frail, Older Patients with Relapsed DLBCL: A Case for Geriatric Assessment and Shared Decision-Making.

2026-09-21T00:00:00Z

Published on 21 September 2026 after first appearing as a preprint; matched Rituximab, Polatuzumab vedotin and Cytotoxic chemotherapy.

21 September 2026.

On OnCo: Rituximab, Polatuzumab vedotin, Cytotoxic chemotherapy, Geriatric assessment

Paper: Clinical Features, Treatment, and Outcomes of Sintilimab-induced Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis.

2026-09-21T00:00:00Z

Published in J Immunother on 21 September 2026; matched the OnCo record for Human normal immunoglobulin.

21 September 2026, J Immunother.

On OnCo: Human normal immunoglobulin

Paper: Code-multiplexed multi-frequency impedance cytometry with a unified deep-unfolding network.

2026-09-21T00:00:00Z

Published on 21 September 2026 after first appearing as a preprint; matched Single-cell & spatial profiling.

21 September 2026.

On OnCo: Single-cell & spatial profiling

Paper: Combination pharmacotherapy for MASH: Potential synergistic approaches.

2026-09-21T00:00:00Z

Published in Biochem Pharmacol on 21 September 2026; matched the OnCo record for THRB.

21 September 2026, Biochem Pharmacol.

On OnCo: THRB

Paper: Comparative Effectiveness of Antibiotic Prophylaxis Regimens in Pediatric Acute Myeloid Leukemia.

2026-09-21T00:00:00Z

Published in Pediatr Blood Cancer on 21 September 2026; matched the OnCo record for Acute myeloid leukaemia in children.

21 September 2026, Pediatr Blood Cancer.

On OnCo: Acute myeloid leukaemia in children

Paper: Correction: Degradation of LMO2 in T cell leukaemia results in collateral breakdown of transcription complex partners and causes LMO2-dependent apoptosis.

2026-09-21T00:00:00Z

Published in Elife on 21 September 2026; matched the OnCo record for LMO2.

21 September 2026, Elife.

On OnCo: LMO2

Paper: Deciphering the apoptotic properties of ergolide, a sesquiterpene lactone form Inula oculus-christi, in hepatocellular carcinoma.

2026-09-21T00:00:00Z

Published in Cytotechnology on 21 September 2026; matched the OnCo record for CASP8.

21 September 2026, Cytotechnology.

On OnCo: CASP8

Paper: Discrepancies in low-value practices across cardiovascular disease prevention guidelines. A narrative review.

2026-09-21T00:00:00Z

Published in Eur J Gen Pract on 21 September 2026; matched the OnCo record for LPA.

21 September 2026, Eur J Gen Pract.

On OnCo: LPA

Paper: Disease-state-themed escape room simulations in undergraduate pharmacy education: A systematic review.

2026-09-21T00:00:00Z

Published on 21 September 2026 after first appearing as a preprint; matched MET, Med-Gemini and MedLM and State.

21 September 2026.

On OnCo: MET, Med-Gemini and MedLM, State

Paper: Effects of Infrared and Dual-Wavelength Photobiomodulation Therapy on Mandibular Bone Healing Following Radiotherapy and Tooth Extraction: An Experimental Study.

2026-09-21T00:00:00Z

Published in J Oral Pathol Med on 21 September 2026; matched the OnCo record for BMP2.

21 September 2026, J Oral Pathol Med.

On OnCo: BMP2

Paper: Endothelial Plasticity as a Continuum in the Tumor Microenvironment.

2026-09-21T00:00:00Z

Published in Vasc Biol on 21 September 2026; matched the OnCo record for TEC.

21 September 2026, Vasc Biol.

On OnCo: TEC

Paper: ER-Localized Deadenylase PNLDC1 Suppresses Colorectal Cancer Progression by Targeting the mRNA Decay of TUBB4B.

2026-09-21T00:00:00Z

Published in Exploration (Beijing) on 21 September 2026; matched the OnCo record for Mebendazole.

21 September 2026, Exploration (Beijing).

On OnCo: Mebendazole, TUBB4B

Paper: Exercise and Intestinal Barrier Integrity: Molecular Mechanisms and Therapeutic Potential in Gut Health and Disease.

2026-09-21T00:00:00Z

Published on 21 September 2026 after first appearing as a preprint; matched NFE2L2.

21 September 2026.

On OnCo: NFE2L2

Paper: Genome-wide DNA methylation landscapes in gallbladder carcinoma: revealing shared and distinct epigenetic signatures across subtypes.

2026-09-21T00:00:00Z

Published in Epigenomics on 21 September 2026; matched the OnCo record for Papillary carcinoma of the gallbladder.

21 September 2026, Epigenomics.

On OnCo: Papillary carcinoma of the gallbladder

Paper: Genome-wide identification of MtTCTPs and functional analysis of MtTCTP3 as a positive regulator of nodulation in Medicago truncatula.

2026-09-21T00:00:00Z

Published in Plant Physiol Biochem on 21 September 2026; matched the OnCo record for TPT1.

21 September 2026, Plant Physiol Biochem.

On OnCo: TPT1

Paper: GMPS drives pancreatic cancer progression via suppressing DNA damage, STING activation and cellular senescence.

2026-09-21T00:00:00Z

Published in Transl Oncol on 21 September 2026; matched the OnCo record for GMPS.

21 September 2026, Transl Oncol.

On OnCo: GMPS

Paper: HSP90 shields ROC1/RBX1 from proteasomal degradation by CHIP E3 ubiquitin ligase to promote lung adenocarcinoma.

2026-09-21T00:00:00Z

Published in Signal Transduct Target Ther on 21 September 2026; matched the OnCo record for RBX1.

21 September 2026, Signal Transduct Target Ther.

On OnCo: RBX1, RIT1

Paper: IL-21 boosts T cell-therapy efficacy for solid tumors by enhancing mitochondrial Ca2+-mediated motility of effector CD8+ T cells.

2026-09-21T00:00:00Z

Published in Cancer Immunol Res on 21 September 2026; matched the OnCo record for TCR-T cell therapy.

21 September 2026, Cancer Immunol Res.

On OnCo: TCR-T cell therapy

Paper: Inducing oxidative stress by targeting the cholesterol biosynthesis pathway augments the efficacy of bortezomib in multiple myeloma.

2026-09-21T00:00:00Z

Published in Free Radic Biol Med on 21 September 2026; matched the OnCo record for FOXO3.

21 September 2026, Free Radic Biol Med.

On OnCo: FOXO3

Paper: Induction and concurrent aumolertinib with radiotherapy for EGFR-mutated stage III NSCLC: results of phase III ADVANCE trial and real-world validation.

2026-09-21T00:00:00Z

Published in Signal Transduct Target Ther on 21 September 2026; matched the OnCo record for Aumolertinib.

21 September 2026, Signal Transduct Target Ther.

On OnCo: Aumolertinib

Paper: Integrative Genetic and Bioinformatic Analysis of Androgen Pathway Gene Polymorphisms, Testosterone, and PSA Levels in Prostate Cancer.

2026-09-21T00:00:00Z

Published in Genet Test Mol Biomarkers on 21 September 2026; matched the OnCo record for CYP17A1.

21 September 2026, Genet Test Mol Biomarkers.

On OnCo: CYP17A1, 5-alpha-reductase type 2

Paper: Intermolecular Hydrogen Bonds Inducing Paramagnetism for Nondestructive CEST Imaging of Nitric Oxide.

2026-09-21T00:00:00Z

Published in Adv Mater on 21 September 2026; matched the OnCo record for CCND2.

21 September 2026, Adv Mater.

On OnCo: CCND2

Paper: Long-Term Benefit With First-Line Osimertinib Monotherapy in EGFR-Mutated Advanced NSCLC in the Era of Intensified First-Line Therapy.

2026-09-21T00:00:00Z

Published in J Thorac Oncol on 21 September 2026; matched the OnCo record for LTB.

21 September 2026, J Thorac Oncol.

On OnCo: LTB

Paper: Longitudinal Analysis of Matched Patient Biospecimens Reveals Neural Reprogramming of Cancer-Associated Fibroblasts Following Chemotherapy in Pancreatic Cancer.

2026-09-21T00:00:00Z

Published on 21 September 2026 after first appearing as a preprint; matched RNA sequencing & expression profiling and Single-cell & spatial profiling.

21 September 2026.

On OnCo: RNA sequencing & expression profiling, Single-cell & spatial profiling

Paper: MATR3 is essential for oocyte growth and maturation quality through a dual molecular mechanism.

2026-09-21T00:00:00Z

Published on 21 September 2026 after first appearing as a preprint; matched KDM3B.

21 September 2026.

On OnCo: KDM3B

Paper: Methodological considerations in defining CBL as a prognostic biomarker in stage II melanoma.

2026-09-21T00:00:00Z

Published in Br J Cancer on 21 September 2026; matched the OnCo record for CBL.

21 September 2026, Br J Cancer.

On OnCo: CBL

Paper: Multi-omics integration identifies prognostic genes linked to adaptive immunity response and radiosensitivity in cervical cancer.

2026-09-21T00:00:00Z

Published in Transl Oncol on 21 September 2026; matched the OnCo record for TCL1A.

21 September 2026, Transl Oncol.

On OnCo: TCL1A

Paper: Multifaceted biological activities of linalool: antimicrobial, antibiofilm, cytotoxic, antiproliferative and caspase-3/7 activity.

2026-09-21T00:00:00Z

Published on 21 September 2026 after first appearing as a preprint; matched PSMA7.

21 September 2026.

On OnCo: PSMA7

Paper: Nutrigenomics and Epigenetic Regulation in Cancer Prevention: Molecular Mechanisms, Dietary Bioactives, and Translational Perspectives.

2026-09-21T00:00:00Z

Published on 21 September 2026 after first appearing as a preprint; matched DNA methylation profiling, Chemoprevention & risk-reducing surgery and Histone deacetylases.

21 September 2026.

On OnCo: DNA methylation profiling, Chemoprevention & risk-reducing surgery, Histone deacetylases

Paper: Otoprotective effect of MnTBAP in cisplatin-induced hearing loss.

2026-09-21T00:00:00Z

Published on 21 September 2026 after first appearing as a preprint; matched Sodium thiosulfate.

21 September 2026.

On OnCo: Sodium thiosulfate

Paper: Phase 1 study of KHK2455, a long-acting, potent and selective IDO1 inhibitor, in combination with avelumab in patients with locally advanced or metastatic urothelial carcinoma.

2026-09-21T00:00:00Z

Published in J Immunother Cancer on 21 September 2026; matched the OnCo record for CCND2.

21 September 2026, J Immunother Cancer.

On OnCo: CCND2

Paper: Radiomics and machine learning for differentiating pediatric intramedullary spinal tumors: a pilot study.

2026-09-21T00:00:00Z

Published in Eur Radiol Exp on 21 September 2026; matched the OnCo record for ITK.

21 September 2026, Eur Radiol Exp.

On OnCo: ITK

Paper: Real-world effectiveness and safety of secukinumab in giant cell arteritis: an Italian multicentre cohort study.

2026-09-21T00:00:00Z

Published in Arthritis Care Res (Hoboken) on 21 September 2026; matched the OnCo record for Tocilizumab.

21 September 2026, Arthritis Care Res (Hoboken).

On OnCo: Tocilizumab

Paper: Ribonucleotides Amplify Mitochondrial DNA-Driven cGAS-STING Activation via FdUMP-ribonucleotide Hybrid Particles to Potentiate Chemoimmunotherapy.

2026-09-21T00:00:00Z

Published in Adv Sci (Weinh) on 21 September 2026; matched the OnCo record for Floxuridine.

21 September 2026, Adv Sci (Weinh).

On OnCo: Floxuridine, TYMP

Paper: Safety and Efficacy of Ceralasertib plus Olaparib for Advanced/Metastatic Triple-Negative Breast Cancer in Three Molecular Strata: The Phase II VIOLETTE Study.

2026-09-21T00:00:00Z

Published in Clin Cancer Res on 21 September 2026; matched the OnCo record for Adavosertib.

21 September 2026, Clin Cancer Res.

On OnCo: Adavosertib, Ceralasertib, WEE1

Paper: SMARCB1 (INI1)-Deficient Undifferentiated Rectal Carcinoma Mimicking Sarcoma: A Case Report and Literature Review.

2026-09-21T00:00:00Z

Published in Clin Case Rep on 21 September 2026; matched the OnCo record for Renal medullary carcinoma.

21 September 2026, Clin Case Rep.

On OnCo: Renal medullary carcinoma, SMARCB1

Paper: Sustained response (ORR4) as an on-treatment prognostic marker in mogamulizumab-treated mycosis fungoides and Sézary syndrome: the FIL-MOGA study.

2026-09-21T00:00:00Z

Published in Br J Dermatol on 21 September 2026; matched the OnCo record for Mogamulizumab.

21 September 2026, Br J Dermatol.

On OnCo: Mogamulizumab

Paper: Targeting CAF-induced oxidative phosphorylation in Dll4+ leader cells with injectable BZA-loaded MPDA hydrogel suppresses collective invasion in salivary adenoid cystic carcinoma.

2026-09-21T00:00:00Z

Published in J Mater Chem B on 21 September 2026; matched the OnCo record for DLL4.

21 September 2026, J Mater Chem B.

On OnCo: DLL4, IL6ST

Paper: Targeting the YAP-BST2 Axis Overcomes Intrinsic Anti-PD-1 Resistance in Metastatic Gastric Cancer.

2026-09-21T00:00:00Z

Published in Adv Sci (Weinh) on 21 September 2026; matched the OnCo record for ATP4B.

21 September 2026, Adv Sci (Weinh).

On OnCo: ATP4B

Paper: The Implementation of NICE Severity Modifier in the Single Technology Appraisal of Mirvetuximab Soravtansine: External Assessment Group Perspective.

2026-09-21T00:00:00Z

Published in Value Health on 21 September 2026; matched the OnCo record for KCNH1.

21 September 2026, Value Health.

On OnCo: KCNH1

Paper: The Situation and Factors Associated with Dental Caries Among Preschool Children in Nakhon Si Thammarat Province, Thailand.

2026-09-21T00:00:00Z

Published on 21 September 2026 after first appearing as a preprint; matched Azacitidine and Decitabine + cedazuridine.

21 September 2026.

On OnCo: Azacitidine, Decitabine + cedazuridine

Paper: Toripalimab Plus TPF as Induction Chemoimmunotherapy for the Treatment of Locally Advanced Hypopharyngeal Carcinoma: A Prospective Phase II Study.

2026-09-21T00:00:00Z

Published in Head Neck on 21 September 2026; matched the OnCo record for Toripalimab.

21 September 2026, Head Neck.

On OnCo: Toripalimab

Paper: Translation, cross-cultural adaptation of longitudinal curriculum objectives in sexual health to Brazilian medical education.

2026-09-21T00:00:00Z

Published in Sex Med on 21 September 2026; matched the OnCo record for NR4A3.

21 September 2026, Sex Med.

On OnCo: NR4A3

Paper: Treatment approaches to macrophage activation syndrome in real life and priorities for future research: results from the international METAPHOR project.

2026-09-21T00:00:00Z

Published in Arthritis Rheumatol on 21 September 2026; matched the OnCo record for Emapalumab.

21 September 2026, Arthritis Rheumatol.

On OnCo: Emapalumab

Paper: Treatment Strategies for Advanced Cutaneous Squamous Cell Carcinoma Following Anti-PD-1 Immunotherapy Failure: A Systematic Review of the Literature and Ongoing Trials.

2026-09-21T00:00:00Z

Published on 21 September 2026 after first appearing as a preprint; matched Oncolytic viruses, EGFR and PD-1.

21 September 2026.

On OnCo: Oncolytic viruses, EGFR, PD-1, Ipilimumab, EGF

Paper: Virotherapy for Spinal and Spinal Cord Tumors: Current Evidence and Future Perspectives.

2026-09-21T00:00:00Z

Published on 21 September 2026 after first appearing as a preprint; matched Oncolytic viruses.

21 September 2026.

On OnCo: Oncolytic viruses

Paper: What happens next: unexpected malignancies after extracapsular dissection of parotid tumors.

2026-09-21T00:00:00Z

Published on 21 September 2026 after first appearing as a preprint; matched MET.

21 September 2026.

On OnCo: MET

Paper: Why Some People Live Past 100: The Role of the Immune System in Centenarians, Semi-Supercentenarians and Supercentenarians.

2026-09-21T00:00:00Z

Published on 21 September 2026 after first appearing as a preprint; matched Single-cell & spatial profiling.

21 September 2026.

On OnCo: Single-cell & spatial profiling

Paper: Circulating tumor DNA-guided de-escalation or escalation of adjuvant therapy in high-risk stage II and stage III colon cancer: the phase 2 PEGASUS trial.

2026-09-14T00:00:00Z

Published in Nat Cancer on 14 September 2026; matched the OnCo record for FOLFIRI.

14 September 2026, Nat Cancer.

On OnCo: FOLFIRI

Paper: Copper ion-induced MYH9 polymerization executes cuproptosis.

2026-09-14T00:00:00Z

Published in Cell on 14 September 2026; matched the OnCo record for MYH9.

14 September 2026, Cell.

On OnCo: MYH9

Paper: P-Loop/αC-Helix Compressing Mutations and Exon 20 Insertions in EGFR-Mutant NSCLC: A Rapidly Evolving Therapeutic Landscape.

2026-09-14T00:00:00Z

Published in J Clin Oncol on 14 September 2026; matched the OnCo record for Afatinib.

14 September 2026, J Clin Oncol.

On OnCo: Afatinib, Amivantamab, Sunvozertinib, Zipalertinib

Paper: Programmed ribosomal frameshifting triggers translational stress to promote viral replication.

2026-09-14T00:00:00Z

Published in Cell on 14 September 2026; matched the OnCo record for NDRG1.

14 September 2026, Cell.

On OnCo: NDRG1

Paper: Advancing neurofibromatosis research: a comparative review of animal models and their utility in dissecting the tumor microenvironment.

2026-09-20T00:00:00Z

Published in Lab Anim Res on 20 September 2026; matched the OnCo record for Genetically engineered mouse models.

20 September 2026, Lab Anim Res.

On OnCo: Genetically engineered mouse models

Paper: Beyond the blood-brain barrier: humanised mice, the missing link in glioblastoma research.

2026-09-20T00:00:00Z

Published in Oncogene on 20 September 2026; matched the OnCo record for Humanised mouse models.

20 September 2026, Oncogene.

On OnCo: Humanised mouse models

Paper: Bone Aging and Glycative Stress: Convergent and Divergent Mechanisms Driving Skeletal Deterioration.

2026-09-20T00:00:00Z

Published on 20 September 2026 after first appearing as a preprint; matched RANK ligand.

20 September 2026.

On OnCo: RANK ligand

Paper: Bridging the data latency gap: automated extraction of genomic biomarkers from unstructured clinical documents to support real-world oncology data.

2026-09-20T00:00:00Z

Published in Cancer Causes Control on 20 September 2026; matched the OnCo record for Oncotype DX.

20 September 2026, Cancer Causes Control.

On OnCo: Oncotype DX

Paper: Current Management and Investigational Therapeutic Strategies in Penile Squamous Cell Carcinoma: A Narrative Review.

2026-09-20T00:00:00Z

Published in Crit Rev Oncol Hematol on 20 September 2026; matched the OnCo record for Penile cancer.

20 September 2026, Crit Rev Oncol Hematol.

On OnCo: Penile cancer

Paper: Dynamic ctDNA Monitoring Predicts Recurrence and Guides Therapy in Postoperative Hepatocellular Carcinoma.

2026-09-20T00:00:00Z

Published in J Surg Oncol on 20 September 2026; matched the OnCo record for ASXL1.

20 September 2026, J Surg Oncol.

On OnCo: ASXL1

Paper: Emerging Patterns of Kidney Cancer in Young Adults: Where Do We Stand? Emerging Patterns of Kidney Cancer in Young Adults: Where Do We Stand?

2026-09-20T00:00:00Z

Published in Crit Rev Oncol Hematol on 20 September 2026; matched the OnCo record for Belzutifan.

20 September 2026, Crit Rev Oncol Hematol.

On OnCo: Belzutifan, Renal medullary carcinoma

Paper: From Damage to Dysregulation: Reframing Oxidative Stress and Redox Homeostasis in Central Nervous System Disease.

2026-09-20T00:00:00Z

Published on 20 September 2026 after first appearing as a preprint; matched State and SET.

20 September 2026.

On OnCo: State, SET

Paper: Genetic and Molecular Determinants of Cancer Therapy-Related Cardiovascular Toxicity.

2026-09-20T00:00:00Z

Published in Cardiovasc Toxicol on 20 September 2026; matched the OnCo record for HER4.

20 September 2026, Cardiovasc Toxicol.

On OnCo: HER4, NRG1, Strain echocardiography, TOP2B

Paper: Lenalidomide maintenance after initial immunochemotherapy in chronic lymphocytic leukaemia-Final analysis of the international phase III CLL6 RESIDUUM study of the ALLG and FILO groups.

2026-09-20T00:00:00Z

Published in Br J Haematol on 20 September 2026; matched the OnCo record for Acute lymphoblastic leukaemia.

20 September 2026, Br J Haematol.

On OnCo: Acute lymphoblastic leukaemia

Paper: Leukemic Stem Cell-Targeted Liposomal Nanoimmunotherapy Reverses Immune Evasion and Inhibits Fusion Oncoprotein-Driven Acute Myeloid Leukemia by Silencing B-Cell Lymphoma 2.

2026-09-20T00:00:00Z

Published in Acta Biomater on 20 September 2026; matched the OnCo record for CD123.

20 September 2026, Acta Biomater.

On OnCo: CD123, MLLT3

Paper: Longitudinal Associations of Oxaliplatin Treatment With Chemotherapy-Induced Peripheral Neuropathy in Colorectal cancer Survivors up to 2 Years Post-Treatment.

2026-09-20T00:00:00Z

Published in Int J Cancer on 20 September 2026; matched the OnCo record for CAPOX.

20 September 2026, Int J Cancer.

On OnCo: CAPOX

Paper: Low-Concentration Enhancement Effect: Enabling Sensitive Detection of EML4-ALK Variants via Multiplex RT-MIRA.

2026-09-20T00:00:00Z

Published in J Clin Lab Anal on 20 September 2026; matched the OnCo record for EML4.

20 September 2026, J Clin Lab Anal.

On OnCo: EML4

Paper: Predictors of perceived value of multi-cancer early detection testing: a national PRECEDE-PROCEED framework study.

2026-09-20T00:00:00Z

Published in Cancer Causes Control on 20 September 2026; matched the OnCo record for Multi-cancer early detection.

20 September 2026, Cancer Causes Control.

On OnCo: Multi-cancer early detection

Paper: Probe-Based Confocal Laser Endomicroscopy During Immune Checkpoint Inhibitor Therapy: A Translational Framework Linking Intestinal Barrier Function, Microbiota, and Clinical Outcomes.

2026-09-20T00:00:00Z

Published on 20 September 2026 after first appearing as a preprint; matched Immune checkpoint inhibitors.

20 September 2026.

On OnCo: Immune checkpoint inhibitors

Paper: Progress with FAK inhibitors in the patent literature (2020-present).

2026-09-20T00:00:00Z

Published in Expert Opin Ther Pat on 20 September 2026; matched the OnCo record for Avutometinib + defactinib.

20 September 2026, Expert Opin Ther Pat.

On OnCo: Avutometinib + defactinib

Paper: Simultaneous multi-pollutant removal from photovoltaic wastewater by aluminum-modified biochar-enhanced partial nitritation-anammox process.

2026-09-20T00:00:00Z

Published in Bioresour Technol on 20 September 2026; matched the OnCo record for Secretory carcinoma of the breast.

20 September 2026, Bioresour Technol.

On OnCo: Secretory carcinoma of the breast

Paper: The p53-Associated Regulation of ATF4 mRNA Expression Involves p21 and p130 in a Stress-Dependent Manner.

2026-09-20T00:00:00Z

Published on 20 September 2026 after first appearing as a preprint; matched CDKN1A.

20 September 2026.

On OnCo: CDKN1A

Paper: Translating avelumab maintenance into clinical practice: nationwide outcomes in Czech patients with advanced or metastatic urothelial carcinoma.

2026-09-20T00:00:00Z

Published in Future Oncol on 20 September 2026; matched the OnCo record for Avelumab.

20 September 2026, Future Oncol.

On OnCo: Avelumab

Paper: Updates to contemporary care of glioblastoma.

2026-09-20T00:00:00Z

Published in Clin Med (Lond) on 20 September 2026; matched the OnCo record for Tumour treating fields.

20 September 2026, Clin Med (Lond).

On OnCo: Tumour treating fields

Paper: Upstream regulatory mechanisms and clinical significance of IQGAP2 deficiency in affecting PI3K activity to drive cell proliferation.

2026-09-20T00:00:00Z

Published in Hum Cell on 20 September 2026; matched the OnCo record for AREG.

20 September 2026, Hum Cell.

On OnCo: AREG, EREG, IQGAP1

Paper: XIST Is a Key Modulator Associated With the Adhesome Network.

2026-09-19T00:00:00Z

Published on 19 September 2026 after first appearing as a preprint; matched Atlas.

19 September 2026.

On OnCo: Atlas

Paper: A pyridone-fused imidazo[1,2-a]pyridine hybrid binds to tubulin at the vinblastine site, depolymerizes microtubules and inhibits Cancer cell proliferation.

2026-09-19T00:00:00Z

Published in Bioorg Chem on 19 September 2026; matched the OnCo record for Vinblastine.

19 September 2026, Bioorg Chem.

On OnCo: Vinblastine

Paper: A systematic review of cancer risks associated with MITF variants.

2026-09-19T00:00:00Z

Published on 19 September 2026 after first appearing as a preprint; matched MITF.

19 September 2026.

On OnCo: MITF

Paper: Acute myeloid leukemia arising in treated chronic lymphocytic leukemia/small lymphocytic lymphoma: a challenge in analysis of lineage relationship.

2026-09-19T00:00:00Z

Published in J Hematop on 19 September 2026; matched the OnCo record for CD123.

19 September 2026, J Hematop.

On OnCo: CD123

Paper: ARID2 Loss Destabilizes PBAF and Drives Colorectal Cancer.

2026-09-19T00:00:00Z

Published in Mol Carcinog on 19 September 2026; matched the OnCo record for ARID1A.

19 September 2026, Mol Carcinog.

On OnCo: ARID1A, ARID1B, ARID2, BRD7, SMARCD1, STAT5, SMARCA4, PBRM1

Paper: Beyond Exons 19 and 21: mapping the clinical and molecular diversity of uncommon EGFR mutations in a Brazilian NSCLC cohort.

2026-09-19T00:00:00Z

Published in Cancer Treat Res Commun on 19 September 2026; matched the OnCo record for STK11.

19 September 2026, Cancer Treat Res Commun.

On OnCo: STK11

Paper: Beyond poly(ADP-ribose) polymerase inhibition: emerging therapeutic strategies for germline BRCA1/2-mutated and PALB2-mutated breast cancers.

2026-09-19T00:00:00Z

Published in Curr Opin Oncol on 19 September 2026; matched the OnCo record for POLQ.

19 September 2026, Curr Opin Oncol.

On OnCo: POLQ, Talazoparib, WEE1

Paper: Blood flow restricted exercise with and without transcutaneous spinal cord stimulation via telehealth in persons with tetraplegia. A protocol for randomized clinical trial.

2026-09-19T00:00:00Z

Published in Spinal Cord on 19 September 2026; matched the OnCo record for Basal-like 1 triple-negative breast cancer.

19 September 2026, Spinal Cord.

On OnCo: Basal-like 1 triple-negative breast cancer, Basal-like 2 triple-negative breast cancer

Paper: Clinicopathologic Characteristics of Somatic TP53 Mutations in Philadelphia Chromosome-Negative Myeloproliferative Neoplasms: A Systematic Review.

2026-09-19T00:00:00Z

Published in EJHaem on 19 September 2026; matched the OnCo record for BCR::ABL1.

19 September 2026, EJHaem.

On OnCo: BCR::ABL1

Paper: CRISPR and Gene Editing Approaches in Prostate Cancer: Clinical Applications and Therapeutic Potential.

2026-09-19T00:00:00Z

Published in Crit Rev Oncol Hematol on 19 September 2026; matched the OnCo record for TMPRSS2.

19 September 2026, Crit Rev Oncol Hematol.

On OnCo: TMPRSS2

Paper: Development of CRISPR_SCD001, an Autologous Hematopoietic Stem Cell Gene Therapy for Sickle Cell Disease after CRISPR-Cas9 Mediated Correction.

2026-09-19T00:00:00Z

Published in Mol Ther on 19 September 2026; matched the OnCo record for HBB.

19 September 2026, Mol Ther.

On OnCo: HBB, Plerixafor

Paper: Distribution, socioeconomic inequalities and contributing factors of anaemia prevalence across wealth index among Indian adolescent girls: multivariate decomposition analysis of nationally representative survey.

2026-09-19T00:00:00Z

Published in BMJ Paediatr Open on 19 September 2026; matched the OnCo record for HB-200.

19 September 2026, BMJ Paediatr Open.

On OnCo: HB-200

Paper: Efficacy and safety of omitting the clinical target volume in limited-stage small cell lung cancer: a large-scale multicenter real-world study.

2026-09-19T00:00:00Z

Published in Radiother Oncol on 19 September 2026; matched the OnCo record for Limited-stage small-cell lung cancer.

19 September 2026, Radiother Oncol.

On OnCo: Limited-stage small-cell lung cancer

Paper: Elucidating the molecular nexus between dental developmental anomalies and chronic inflammatory diseases: A computational systems biology analysis of genomic sequence homology using matrix factorization.

2026-09-19T00:00:00Z

Published in Comput Biol Chem on 19 September 2026; matched the OnCo record for MERTK.

19 September 2026, Comput Biol Chem.

On OnCo: MERTK

Paper: Five-year outcomes of partial breast proton beam therapy without lumpectomy for early-stage breast cancer: an interventional prospective study.

2026-09-19T00:00:00Z

Published on 19 September 2026 after first appearing as a preprint; matched MRI, Proton therapy and Estrogen receptor.

19 September 2026.

On OnCo: MRI, Proton therapy, Estrogen receptor, EGF

Paper: Gastrodin enhances the spleen immune function in erythroleukemia by regulating T-cell receptor signaling pathway.

2026-09-19T00:00:00Z

Published in Med Oncol on 19 September 2026; matched the OnCo record for ITK.

19 September 2026, Med Oncol.

On OnCo: ITK, LCK

Paper: Head-to-head comparison of [¹⁸F]F-PSMA-1007 PET/CT and [⁶⁸Ga]Ga-PSMA-11 PET/CT for intraprostatic tumour detection and localisation using histopathology as reference: A prospective single-centre diagnostic accuracy study.

2026-09-19T00:00:00Z

Published in Eur J Nucl Med Mol Imaging on 19 September 2026; matched the OnCo record for Gallium-68 gozetotide.

19 September 2026, Eur J Nucl Med Mol Imaging.

On OnCo: Gallium-68 gozetotide

Paper: Hepatocellular Carcinoma With a Grade 3 Neuroendocrine Tumor Component: A Case Report.

2026-09-19T00:00:00Z

Published in Int J Surg Pathol on 19 September 2026; matched the OnCo record for Grade 3 well-differentiated neuroendocrine tumour.

19 September 2026, Int J Surg Pathol.

On OnCo: Grade 3 well-differentiated neuroendocrine tumour

Paper: Immunogenic cell death as a mechanism of synergy between sunitinib and 177Lu-DOTATATE peptide receptor radionuclide therapy in pancreatic neuroendocrine tumors.

2026-09-19T00:00:00Z

Published in Cell Death Discov on 19 September 2026; matched the OnCo record for Lutetium-177 dotatate.

19 September 2026, Cell Death Discov.

On OnCo: Lutetium-177 dotatate, Pancreatic neuroendocrine tumours

Paper: In vivo CAR‑T cell therapy: mechanisms, clinical advances and optimization strategies.

2026-09-19T00:00:00Z

Published in Biochem Pharmacol on 19 September 2026; matched the OnCo record for In vivo CAR-T.

19 September 2026, Biochem Pharmacol.

On OnCo: In vivo CAR-T

Paper: Integrating immunophenotyping and morphology in the diagnosis of acute leukemia at the National Oncology Center, Sana'a, Yemen.

2026-09-19T00:00:00Z

Published in Libyan J Med on 19 September 2026; matched the OnCo record for Anal high-grade squamous intraepithelial lesions.

19 September 2026, Libyan J Med.

On OnCo: Anal high-grade squamous intraepithelial lesions, Burkitt lymphoma, CD19, CD7

Paper: Investigating the impact of margins on the management of oropharyngeal cancer treated with transoral robotic surgery: a survey of head and neck oncologists' treatment patterns.

2026-09-19T00:00:00Z

Published in Oral Oncol on 19 September 2026; matched the OnCo record for Transoral robotic surgery.

19 September 2026, Oral Oncol.

On OnCo: Transoral robotic surgery

Paper: IRF1-driven chromatin and transcriptional regulation determines the anti-tumor responses to all-trans retinoic acid across cancer types.

2026-09-19T00:00:00Z

Published in Biochem Pharmacol on 19 September 2026; matched the OnCo record for Acute promyelocytic leukaemia.

19 September 2026, Biochem Pharmacol.

On OnCo: Acute promyelocytic leukaemia, IRF1

Paper: Lenalidomide triggers ferroptosis in multiple myeloma by blocking the c-Maf/USP7 signaling pathway to induce the ubiquitination and degradation of FTH1.

2026-09-19T00:00:00Z

Published in Cell Signal on 19 September 2026; matched the OnCo record for MAF.

19 September 2026, Cell Signal.

On OnCo: MAF

Paper: MicroRNA-122 as a regulator and biomarker of liver disease.

2026-09-19T00:00:00Z

Published in J Mol Med (Berl) on 19 September 2026; matched the OnCo record for FOXO3.

19 September 2026, J Mol Med (Berl).

On OnCo: FOXO3

Paper: Neuregulin-1 as a Context-Dependent Regulator of Neuroinflammation and Neural Repair: Mechanisms, Disease Relevance, and Therapeutic Challenges.

2026-09-19T00:00:00Z

Published on 19 September 2026 after first appearing as a preprint; matched HER2, HER4 and NRG1.

19 September 2026.

On OnCo: HER2, HER4, NRG1, EGF

Paper: PAX9 activates autophagy through a transcription-dependent mechanism, promoting EGFR degradation to restrict cell survival in oral cancer.

2026-09-19T00:00:00Z

Published in Br J Cancer on 19 September 2026; matched the OnCo record for PAX9.

19 September 2026, Br J Cancer.

On OnCo: PAX9

Paper: Precision therapeutic strategies for advanced gastrointestinal stromal tumors.

2026-09-19T00:00:00Z

Published in Cancer Metastasis Rev on 19 September 2026; matched the OnCo record for Ripretinib.

19 September 2026, Cancer Metastasis Rev.

On OnCo: Ripretinib

Paper: Prognostic Associations of Molecular MRD and Genomic Features in ZNF384-Rearranged B-ALL Undergoing Allo-HSCT.

2026-09-19T00:00:00Z

Published in Transplant Cell Ther on 19 September 2026; matched the OnCo record for CD33.

19 September 2026, Transplant Cell Ther.

On OnCo: CD33, ETV6, IKZF1, TCF3

Paper: Real-World Treatment Patterns, Healthcare Resource Use, and Costs in Patients with Follicular Lymphoma, Waldenström Macroglobulinemia, and Marginal Zone Lymphoma: A Claims-Based Study in the USA.

2026-09-19T00:00:00Z

Published in Clin Drug Investig on 19 September 2026; matched the OnCo record for Bendamustine.

19 September 2026, Clin Drug Investig.

On OnCo: Bendamustine

Paper: Regulatory roles of G-quadruplexes and G-quadruplex-binding proteins across the enhancer and promoter of the HBV genome.

2026-09-19T00:00:00Z

Published in Virol J on 19 September 2026; matched the OnCo record for CNBP.

19 September 2026, Virol J.

On OnCo: CNBP

Paper: ROS-Activated SHP-1 Signaling Underlies Artesunate-Mediated Inhibition of EMT and STAT3-Driven Prostate Cancer Progression.

2026-09-19T00:00:00Z

Published in Arch Biochem Biophys on 19 September 2026; matched the OnCo record for PTPN6.

19 September 2026, Arch Biochem Biophys.

On OnCo: PTPN6

Paper: Salivary Duct Carcinoma With Rhabdoid and Signet-Ring Cell Features Mimicking Invasive Lobular Carcinoma of the Breast: A Case Report and Review of the Literature.

2026-09-19T00:00:00Z

Published in Int J Surg Pathol on 19 September 2026; matched the OnCo record for Invasive lobular carcinoma of the breast.

19 September 2026, Int J Surg Pathol.

On OnCo: Invasive lobular carcinoma of the breast, Salivary duct carcinoma

Paper: SOX17 and TRPS1 in Müllerian, Breast, and Mesothelial Tumors: Tissue-Based Specificity Profiles and Diagnostic Pitfalls in Malignant Serous Effusions.

2026-09-19T00:00:00Z

Published in Int J Surg Pathol on 19 September 2026; matched the OnCo record for SOX17.

19 September 2026, Int J Surg Pathol.

On OnCo: SOX17, TRPS1

Paper: Stepwise neutrophil-to-neuron targeting nanotherapy for mitochondrial protection and blood-brain barrier preservation in ischemic stroke.

2026-09-19T00:00:00Z

Published in J Control Release on 19 September 2026; matched the OnCo record for TET1.

19 September 2026, J Control Release.

On OnCo: TET1

Paper: Strategies to prevent post-transplant relapse in acute myeloid leukemia and myelodysplastic syndromes.

2026-09-19T00:00:00Z

Published in Int J Hematol on 19 September 2026; matched the OnCo record for Decitabine.

19 September 2026, Int J Hematol.

On OnCo: Decitabine, Quizartinib

Paper: Summary of Research: HER2CLIMB-05: A Phase III Study of Tucatinib Versus Placebo in Combination with Trastuzumab and Pertuzumab as First-Line Maintenance Therapy for HER2+ Metastatic Breast Cancer.

2026-09-19T00:00:00Z

Published in Target Oncol on 19 September 2026; matched the OnCo record for Tucatinib.

19 September 2026, Target Oncol.

On OnCo: Tucatinib

Paper: TAPESTRY study: impact of prior transurethral resection of the prostate on outcomes after robot-assisted radical prostatectomy: a propensity score-matched cohort study.

2026-09-19T00:00:00Z

Published on 19 September 2026 after first appearing as a preprint; matched KLK3.

19 September 2026.

On OnCo: KLK3

Paper: Tarlatamab in small cell lung cancer following platinum-based chemotherapy: subgroup analysis of Japanese patients from the DeLLphi-304 study.

2026-09-19T00:00:00Z

Published in Int J Clin Oncol on 19 September 2026; matched the OnCo record for Amrubicin.

19 September 2026, Int J Clin Oncol.

On OnCo: Amrubicin

Paper: The AURKA-PTTG1 signaling axis induces enzalutamide resistance in prostate cancer.

2026-09-19T00:00:00Z

Published in Urol Oncol on 19 September 2026; matched the OnCo record for PTTG1.

19 September 2026, Urol Oncol.

On OnCo: PTTG1

Paper: The Relationship Between Lichen Planus and Thyroid Disorders in an Iranian Population: A Case-Control Study.

2026-09-19T00:00:00Z

Published in Health Sci Rep on 19 September 2026; matched the OnCo record for LPP.

19 September 2026, Health Sci Rep.

On OnCo: LPP

Paper: Transoral Robotic Surgery (TORS) versus radical radiotherapy following neoadjuvant therapy for oropharyngeal carcinoma: a multicenter, real-world efficacy and safety analysis.

2026-09-19T00:00:00Z

Published in J Robot Surg on 19 September 2026; matched the OnCo record for Transoral robotic surgery.

19 September 2026, J Robot Surg.

On OnCo: Transoral robotic surgery

Paper: TRIM28 facilitates diffuse large B-cell lymphoma progression by inducing glycolytic reprogramming through the E2F1/PKM2 axis.

2026-09-19T00:00:00Z

Published in Naunyn Schmiedebergs Arch Pharmacol on 19 September 2026; matched the OnCo record for TRIM28.

19 September 2026, Naunyn Schmiedebergs Arch Pharmacol.

On OnCo: TRIM28

Paper: Tumor-cell HMGB1 restrains CD8+ T-cell immunity during conventional fractionated radiotherapy.

2026-09-19T00:00:00Z

Published in Cancer Lett on 19 September 2026; matched the OnCo record for TCF4.

19 September 2026, Cancer Lett.

On OnCo: TCF4, TCF7L2

Paper: Uterine NTRK-Rearranged Spindle Cell Neoplasm With Unusual Morphology-A Case Report and Literature Review.

2026-09-19T00:00:00Z

Published in Int J Surg Pathol on 19 September 2026; matched the OnCo record for TPM3.

19 September 2026, Int J Surg Pathol.

On OnCo: TPM3

Paper: Viral exploitation of p300/CBP at the virus-cancer interface: Chromatin regulation, oncogenesis, immune evasion, and therapeutic targeting.

2026-09-19T00:00:00Z

Published in Cancer Treat Res Commun on 19 September 2026; matched the OnCo record for CREBBP.

19 September 2026, Cancer Treat Res Commun.

On OnCo: CREBBP

Paper: Virtual screening of Kv1.3 inhibitors and investigation of their molecular mechanisms in alleviating alcoholic liver injury in mice.

2026-09-19T00:00:00Z

Published in Eur J Med Chem on 19 September 2026; matched the OnCo record for KCNA3.

19 September 2026, Eur J Med Chem.

On OnCo: KCNA3

Paper: Tambotatug Pelitecan in Small-Cell Lung Cancer after Platinum-Based Therapy.

2026-09-12T00:00:00Z

Published in N Engl J Med on 12 September 2026; matched the OnCo record for YL201.

12 September 2026, N Engl J Med.

On OnCo: YL201

Paper: [Corrigendum] The interaction between miR‑148a and DNMT1 suppresses cell migration and invasion by reactivating tumor suppressor genes in pancreatic cancer.

2026-09-18T00:00:00Z

Published in Oncol Rep on 18 September 2026; matched the OnCo record for DNMT1.

18 September 2026, Oncol Rep.

On OnCo: DNMT1

Paper: [Corrigendum] TIP60 governs the auto‑ubiquitination of UHRF1 through USP7 dissociation from the UHRF1/USP7 complex.

2026-09-18T00:00:00Z

Published in Int J Oncol on 18 September 2026; matched the OnCo record for KAT5.

18 September 2026, Int J Oncol.

On OnCo: KAT5, USP7

Paper: [Update on anal dysplasia and anal cancer].

2026-09-18T00:00:00Z

Published in Dermatologie (Heidelb) on 18 September 2026; matched the OnCo record for Metastatic and recurrent anal squamous cell carcinoma.

18 September 2026, Dermatologie (Heidelb).

On OnCo: Metastatic and recurrent anal squamous cell carcinoma, Retifanlimab

Paper: A canonical role of SMAD4 in safeguarding 3D genome architecture to suppress lung tumorigenesis.

2026-09-18T00:00:00Z

Published in Oncogene on 18 September 2026; matched the OnCo record for ELF3.

18 September 2026, Oncogene.

On OnCo: ELF3, Genetically engineered mouse models

Paper: A four‑gene signature identifies TKI‑induced persister cells and uncovers a ZLN005‑induced pyroptotic vulnerability via the GSDME pathway in EGFR‑mutant lung cancer.

2026-09-18T00:00:00Z

Published in Mol Med Rep on 18 September 2026; matched the OnCo record for EGFR-mutated non-small-cell lung cancer.

18 September 2026, Mol Med Rep.

On OnCo: EGFR-mutated non-small-cell lung cancer, NCOA1

Paper: A phase IIa study of the anti-PD-L1 antibody avelumab in relapsed/refractory PTCL: The AVAIL-T trial.

2026-09-18T00:00:00Z

Published in Br J Haematol on 18 September 2026; matched the OnCo record for Avelumab.

18 September 2026, Br J Haematol.

On OnCo: Avelumab

Paper: Acute Myocardial Infarction in Head and Neck Cancer Patients and Survivors: A Population-Based Cohort Study of Patient, Disease, and Treatment Factors.

2026-09-18T00:00:00Z

Published in Clin Oncol (R Coll Radiol) on 18 September 2026; matched the OnCo record for Hypopharyngeal cancer.

18 September 2026, Clin Oncol (R Coll Radiol).

On OnCo: Hypopharyngeal cancer

Paper: An Accessible Approach to Molecular and Biomarker Testing for Risk Stratification in Oral Cavity Squamous Cell Carcinoma.

2026-09-18T00:00:00Z

Published in Head Neck Pathol on 18 September 2026; matched the OnCo record for CDKN2B.

18 September 2026, Head Neck Pathol.

On OnCo: CDKN2B, FGF19, FGF3, FGF4, HRAS

Paper: Anagrelide remodels the PDE3A-SLFN12 interactome to associate with translation initiation machinery in cancer cell lines.

2026-09-18T00:00:00Z

Published in Mol Cell Proteomics on 18 September 2026; matched the OnCo record for Anagrelide.

18 September 2026, Mol Cell Proteomics.

On OnCo: Anagrelide, PDE3A

Paper: Artificial Intelligence in Digital Pathology for Prostate Cancer Detection: FDA Clearance and Real-World Implementation.

2026-09-18T00:00:00Z

Published in J Clin Pathol on 18 September 2026; matched the OnCo record for Paige Prostate Detect.

18 September 2026, J Clin Pathol.

On OnCo: Paige Prostate Detect

Paper: Autophagy inhibition sensitizes radiotherapy responses in high-grade mutant IDH1 glioma.

2026-09-18T00:00:00Z

Published in Nat Commun on 18 September 2026; matched the OnCo record for ATG7.

18 September 2026, Nat Commun.

On OnCo: ATG7

Paper: Beyond Anatomical Resectability: A Hypermetabolic and Highly Aggressive Subtype of Spinal Chordoma Associated with Cancer-Specific Progression.

2026-09-18T00:00:00Z

Published in Spine J on 18 September 2026; matched the OnCo record for Chordoma.

18 September 2026, Spine J.

On OnCo: Chordoma

Paper: Beyond the T-Score: A Narrative Clinical Review of Adult Endocrine Osteoporosis Care.

2026-09-18T00:00:00Z

Published on 18 September 2026 after first appearing as a preprint; matched Denosumab.

18 September 2026.

On OnCo: Denosumab

Paper: Beyond Traditional Prognostic Scores: Associations of Organ Dysfunction and Metastatic Malignancy with Mortality in Fournier's Gangrene.

2026-09-18T00:00:00Z

Published on 18 September 2026 after first appearing as a preprint; matched MET.

18 September 2026.

On OnCo: MET

Paper: BUB1B Mitotic Kinase Dependency Reveals CENP-E Inhibition as a Tractable Approach for Castration and Enzalutamide Resistant Prostate Cancer.

2026-09-18T00:00:00Z

Published in Cancer Res on 18 September 2026; matched the OnCo record for BUB1B.

18 September 2026, Cancer Res.

On OnCo: BUB1B

Paper: Can early 68Ga-PSMA-11 PET/CT predict 6-month disease control in patients receiving first-line systemic therapy for metastatic clear-cell renal cell carcinoma? Protocol for the multicentre prospective phase II PSMA-RENAL study in Belgium.

2026-09-18T00:00:00Z

Published in BMJ Open on 18 September 2026; matched the OnCo record for Gallium-68 gozetotide.

18 September 2026, BMJ Open.

On OnCo: Gallium-68 gozetotide

Paper: Carbohydrate-Directed Labeling Probes for UV-Independent Chemoproteomic Profiling of Carbohydrate-Protein Interactions.

2026-09-18T00:00:00Z

Published in Angew Chem Int Ed Engl on 18 September 2026; matched the OnCo record for CD22.

18 September 2026, Angew Chem Int Ed Engl.

On OnCo: CD22

Paper: CD28-ICOS costimulation enhances the therapeutic efficacy of L1CAM-targeted CAR-T cells against ovarian and gastric cancers.

2026-09-18T00:00:00Z

Published in J Immunother Cancer on 18 September 2026; matched the OnCo record for ICOS.

18 September 2026, J Immunother Cancer.

On OnCo: ICOS

Paper: Chemotherapy Versus Surgery for Stage IIA Nonseminomatous Germ Cell Tumor: A Comparative Cost Utility Analysis.

2026-09-18T00:00:00Z

Published in J Urol on 18 September 2026; matched the OnCo record for Testicular germ cell tumours.

18 September 2026, J Urol.

On OnCo: Testicular germ cell tumours

Paper: Circulating Tumor DNA (ctDNA) Clearance After Immune Checkpoint Inhibition (ICI) with Radiotherapy (RT) as a Prognostic Biomarker for Advanced Melanoma.

2026-09-18T00:00:00Z

Published on 18 September 2026 after first appearing as a preprint; matched Liquid biopsy.

18 September 2026.

On OnCo: Liquid biopsy

Paper: Class visualizations and activation atlases for computational pathology.

2026-09-18T00:00:00Z

Published in Cell Rep Med on 18 September 2026; matched the OnCo record for Pathology & radiology foundation models.

18 September 2026, Cell Rep Med.

On OnCo: Pathology & radiology foundation models

Paper: Claudin 18.2 Expression and Outcomes in Resected Gallbladder and Biliary Tract Adenocarcinomas: A Pilot Clinicopathologic Study.

2026-09-18T00:00:00Z

Published in Int J Surg Pathol on 18 September 2026; matched the OnCo record for VENTANA PD-L1 (SP263) Assay.

18 September 2026, Int J Surg Pathol.

On OnCo: VENTANA PD-L1 (SP263) Assay

Paper: Cobalt-mediated suppression of IFN-γ-JAK-STAT1 signaling reprograms IDO1-driven immunosuppression for metalloimmunotherapy.

2026-09-18T00:00:00Z

Published in Sci Adv on 18 September 2026; matched the OnCo record for IFNGR1.

18 September 2026, Sci Adv.

On OnCo: IFNGR1

Paper: Combination of Immune Checkpoint Inhibitors With Vascular Endothelial Growth Factor-Targeted Agents in Advanced Gastric and Gastroesophageal Adenocarcinoma: A Systematic Review and Meta-analysis.

2026-09-18T00:00:00Z

Published in Am J Clin Oncol on 18 September 2026; matched the OnCo record for Rivoceranib.

18 September 2026, Am J Clin Oncol.

On OnCo: Rivoceranib

Paper: Communicating Change on Multi-item Patient-Reported Outcome Measures: What Were the Meaningful Changes in Physical Functioning Experienced by Patients on Vimseltinib in the MOTION Trial.

2026-09-18T00:00:00Z

Published in Patient on 18 September 2026; matched the OnCo record for Vimseltinib.

18 September 2026, Patient.

On OnCo: Vimseltinib

Paper: Community-Based Skin Cancer Screening and Follow-up Outcomes from a Statewide Outreach Program.

2026-09-18T00:00:00Z

Published in J Am Acad Dermatol on 18 September 2026; matched the OnCo record for Skin cancer screening.

18 September 2026, J Am Acad Dermatol.

On OnCo: Skin cancer screening

Paper: Compartment-specific CD8 infiltration and disease-specific survival in resected ampullary adenocarcinoma.

2026-09-18T00:00:00Z

Published in Cancer Res Commun on 18 September 2026; matched the OnCo record for Ampullary cancer.

18 September 2026, Cancer Res Commun.

On OnCo: Ampullary cancer

Paper: CT-based deep foundation model for predicting immune checkpoint inhibitor-induced pneumonitis risk in lung cancer.

2026-09-18T00:00:00Z

Published on 18 September 2026 after first appearing as a preprint; matched Nintedanib, Immune checkpoint inhibitors and Radiomics.

18 September 2026.

On OnCo: Nintedanib, Immune checkpoint inhibitors, Radiomics, SET

Paper: Defective neuronal differentiation in Lowe syndrome is associated with mitochondrial dysfunction and impaired cilia-related Sonic Hedgehog signaling.

2026-09-18T00:00:00Z

Published on 18 September 2026 after first appearing as a preprint; matched Smoothened.

18 September 2026.

On OnCo: Smoothened

Paper: Demethylase FTO attenuates atherosclerotic plaque via upregulating ABCA1 and ABCG1 expression by targeting ATG5.

2026-09-18T00:00:00Z

Published in Mol Med Rep on 18 September 2026; matched the OnCo record for FTO.

18 September 2026, Mol Med Rep.

On OnCo: FTO

Paper: DGKα and ζ deficiency causes regulatory T-cell dysregulation, destabilization, and conversion to pathogenic T-follicular helper cells to trigger IgG1-predominant autoimmunity.

2026-09-18T00:00:00Z

Published on 18 September 2026 after first appearing as a preprint; matched CD28.

18 September 2026.

On OnCo: CD28

Paper: Disseminated Fusarium infection following cladribine chemotherapy for hairy-cell leukaemia.

2026-09-18T00:00:00Z

Published in BMJ Case Rep on 18 September 2026; matched the OnCo record for Cladribine.

18 September 2026, BMJ Case Rep.

On OnCo: Cladribine, Hairy cell leukaemia

Paper: Effect of transcutaneous auricular vagus nerve stimulation on postoperative gastrointestinal dysfunction in patients with gynecological abdominal or pelvic tumors: a study protocol for a prospective, single-center, randomized, controlled clinical trial.

2026-09-18T00:00:00Z

Published in Ann Med on 18 September 2026; matched the OnCo record for Stage III melanoma.

18 September 2026, Ann Med.

On OnCo: Stage III melanoma

Paper: Efficacy and safety analysis of disitamab vedotin combined with immunotherapy as neoadjuvant treatment to promote conversion to bladder preservation in bladder cancer: A retrospective comparative study with the GC combined with immunotherapy regimen.

2026-09-18T00:00:00Z

Published in Urol Oncol on 18 September 2026; matched the OnCo record for Gemcitabine + cisplatin.

18 September 2026, Urol Oncol.

On OnCo: Gemcitabine + cisplatin, Toripalimab

Paper: Efficacy and safety of proton radiotherapy for progressive or surgically unfavorable adult pilocytic astrocytoma: a single-center experience.

2026-09-18T00:00:00Z

Published in J Neurooncol on 18 September 2026; matched the OnCo record for Paediatric low-grade glioma.

18 September 2026, J Neurooncol.

On OnCo: Paediatric low-grade glioma

Paper: Emerging role of targeted therapy in drug-resistant epilepsy in patients with glioma.

2026-09-18T00:00:00Z

Published in Curr Opin Oncol on 18 September 2026; matched the OnCo record for Vorasidenib.

18 September 2026, Curr Opin Oncol.

On OnCo: Vorasidenib

Paper: Eomesodermin in renal cell carcinoma: Epigenetic and immune crosstalk driving tumor progression (Review).

2026-09-18T00:00:00Z

Published in Int J Oncol on 18 September 2026; matched the OnCo record for EOMES.

18 September 2026, Int J Oncol.

On OnCo: EOMES

Paper: Erythematous dorsal plaques in 6 patients with advanced T-cell lymphoma: a clinical variant of mogamulizumab-associated rash.

2026-09-18T00:00:00Z

Published in Actas Dermosifiliogr on 18 September 2026; matched the OnCo record for Mogamulizumab.

18 September 2026, Actas Dermosifiliogr.

On OnCo: Mogamulizumab

Paper: Evolutionary rescue model informs strategies for driving cancer cell populations to extinction.

2026-09-18T00:00:00Z

Published on 18 September 2026 after first appearing as a preprint; matched State.

18 September 2026.

On OnCo: State

Paper: Exploratory single-nucleus transcriptomic analysis of endothelial heterogeneity and ferroptosis-related gene patterns in a human hepatocellular carcinoma sample.

2026-09-18T00:00:00Z

Published in Transl Oncol on 18 September 2026; matched the OnCo record for HSPG2.

18 September 2026, Transl Oncol.

On OnCo: HSPG2

Paper: FDG-PET/CT-based treatment response predicts recurrence and overall survival in locally advanced cervical cancer.

2026-09-18T00:00:00Z

Published in BMC Med Imaging on 18 September 2026; matched the OnCo record for Locally advanced cervical cancer.

18 September 2026, BMC Med Imaging.

On OnCo: Locally advanced cervical cancer, Recurrent or metastatic cervical cancer

Paper: Feasibility of prostate offline adaptive radiation therapy using iterative reconstructed CBCT to optimize the ART workflow.

2026-09-18T00:00:00Z

Published in Phys Med on 18 September 2026; matched the OnCo record for MR-guided adaptive radiotherapy.

18 September 2026, Phys Med.

On OnCo: MR-guided adaptive radiotherapy

Paper: Frailty of older patients is not reflected in the melanoma tumor microenvironment and treatment response to immune checkpoint blockade therapy.

2026-09-18T00:00:00Z

Published in J Immunother Cancer on 18 September 2026; matched the OnCo record for Imaging mass cytometry.

18 September 2026, J Immunother Cancer.

On OnCo: Imaging mass cytometry

Paper: Gene regulatory elements determine efficacy of BCMA-targeted CAR-T cell products.

2026-09-18T00:00:00Z

Published in J Immunother Cancer on 18 September 2026; matched the OnCo record for Ciltacabtagene autoleucel.

18 September 2026, J Immunother Cancer.

On OnCo: Ciltacabtagene autoleucel, Idecabtagene vicleucel

Paper: Germline cancer predisposition gene mutations and upgrade rate to breast cancer among patients with pleomorphic and florid lobular carcinoma in situ.

2026-09-18T00:00:00Z

Published in Hum Pathol on 18 September 2026; matched the OnCo record for Lobular carcinoma in situ.

18 September 2026, Hum Pathol.

On OnCo: Lobular carcinoma in situ

Paper: Grass carp reovirus activates fish Ppp1r3g to suppress innate immunity and exacerbate hemorrhage via the 14-3-3ζ/Itgb3 signaling axis.

2026-09-18T00:00:00Z

Published in PLoS Pathog on 18 September 2026; matched the OnCo record for ITGB3.

18 September 2026, PLoS Pathog.

On OnCo: ITGB3

Paper: Hepatitis B virus proteome analysis identifies apolipoprotein C1 facilitating particle production and virus entry.

2026-09-18T00:00:00Z

Published in Hepatology on 18 September 2026; matched the OnCo record for HSP90AB1.

18 September 2026, Hepatology.

On OnCo: HSP90AB1, LPA

Paper: Indirect treatment comparison of odevixibat and maralixibat for the treatment of cholestatic pruritus in patients with Alagille syndrome.

2026-09-18T00:00:00Z

Published in J Comp Eff Res on 18 September 2026; matched the OnCo record for Small intestine cancer.

18 September 2026, J Comp Eff Res.

On OnCo: Small intestine cancer

Paper: Integrative single-cell and spatial transcriptomic analyses identify LMX1B as a tumor suppressor orchestrating the GDF15-ATP4B axis in renal cell carcinoma.

2026-09-18T00:00:00Z

Published in Transl Oncol on 18 September 2026; matched the OnCo record for ATP4B.

18 September 2026, Transl Oncol.

On OnCo: ATP4B, LMX1B

Paper: Investigating the clinical utility of plasma succinate with insights from a Sdhb deficient murine model.

2026-09-18T00:00:00Z

Published in Endocr Relat Cancer on 18 September 2026; matched the OnCo record for SDHA.

18 September 2026, Endocr Relat Cancer.

On OnCo: SDHA, SDHB, SDHC, SDHD

Paper: Loncastuximab tesirine in heavily pretreated patients with large B-cell lymphoma: a German Lymphoma Alliance analysis.

2026-09-18T00:00:00Z

Published in Blood Adv on 18 September 2026; matched the OnCo record for Allogeneic stem cell transplantation.

18 September 2026, Blood Adv.

On OnCo: Allogeneic stem cell transplantation, Loncastuximab tesirine

Paper: Manganese dioxide nanoparticles attenuate pathological retinal angiogenesis by inhibiting the PLK1/AKT/FOXO1 signaling axis.

2026-09-18T00:00:00Z

Published in Biomed Mater on 18 September 2026; matched the OnCo record for PLK1.

18 September 2026, Biomed Mater.

On OnCo: PLK1

Paper: Mechanisms and disease relevance of DNA break repair pathway choice.

2026-09-18T00:00:00Z

Published in Nat Rev Mol Cell Biol on 18 September 2026; matched the OnCo record for BARD1.

18 September 2026, Nat Rev Mol Cell Biol.

On OnCo: BARD1, TP53BP1

Paper: Medulloblastoma-associated mutations in the RNA helicase DDX3X/DED1 cause defects in the translational response to TORC1 inhibition.

2026-09-18T00:00:00Z

Published in J Biol Chem on 18 September 2026; matched the OnCo record for CRTC1.

18 September 2026, J Biol Chem.

On OnCo: CRTC1, DDX3X

Paper: Metabolic modulation of glioblastoma by dietary intervention: a systematic review.

2026-09-18T00:00:00Z

Published on 18 September 2026 after first appearing as a preprint; matched Bevacizumab, Bevacizumab and Anti-angiogenic therapy.

18 September 2026.

On OnCo: Bevacizumab, Bevacizumab, Anti-angiogenic therapy

Paper: MH-Penile-002: a phase II, prospective, single-arm trial of neoadjuvant anti-EGFR antibody-drug conjugate plus PD-1 inhibitor in penile cancer with challenging penile preservation or regional lymph node metastasis.

2026-09-18T00:00:00Z

Published in Future Oncol on 18 September 2026; matched the OnCo record for Node-positive and metastatic penile cancer.

18 September 2026, Future Oncol.

On OnCo: Node-positive and metastatic penile cancer, Pucotenlimab

Paper: Modulating pseudokinase conformation from the ATP-binding site.

2026-09-18T00:00:00Z

Published in Structure on 18 September 2026; matched the OnCo record for EPHA10.

18 September 2026, Structure.

On OnCo: EPHA10, HER3

Paper: Molecular Response, Event-Free Survival, and Treatment-Free Remission in Myeloproliferative Neoplasms: Update and Review with Insights from MPN Asia 2026.

2026-09-18T00:00:00Z

Published in Curr Hematol Malig Rep on 18 September 2026; matched the OnCo record for Ropeginterferon alfa-2b.

18 September 2026, Curr Hematol Malig Rep.

On OnCo: Ropeginterferon alfa-2b

Paper: Molecular targeted therapy for thyroid cancer in Japan: Current status and future perspectives.

2026-09-18T00:00:00Z

Published in Auris Nasus Larynx on 18 September 2026; matched the OnCo record for Companion diagnostics.

18 September 2026, Auris Nasus Larynx.

On OnCo: Companion diagnostics

Paper: Multiparametric Whole-Body MRI Protocols in Contemporary Clinical Practice: Indications, Technical Considerations, and Emerging Applications.

2026-09-18T00:00:00Z

Published in J Comput Assist Tomogr on 18 September 2026; matched the OnCo record for Whole-body MRI.

18 September 2026, J Comput Assist Tomogr.

On OnCo: Whole-body MRI

Paper: NHSL3 knockout modulates sorafenib response, growth, and motility in hepatocellular carcinoma cell models.

2026-09-18T00:00:00Z

Published in Mol Biol Rep on 18 September 2026; matched the OnCo record for CRAF.

18 September 2026, Mol Biol Rep.

On OnCo: CRAF

Paper: Non-canonical Wnt11/PCP/YAP signaling mediates epithelial-mesenchymal transition and immunosuppressive tumor microenvironment in colorectal cancer.

2026-09-18T00:00:00Z

Published in Int Immunopharmacol on 18 September 2026; matched the OnCo record for WNT11.

18 September 2026, Int Immunopharmacol.

On OnCo: WNT11

Paper: Nucleolar METTL16 drives ccRCC tumorigenesis and pazopanib resistance via translational activation of JAG1/Notch signaling pathway.

2026-09-18T00:00:00Z

Published in Drug Resist Updat on 18 September 2026; matched the OnCo record for JAG1.

18 September 2026, Drug Resist Updat.

On OnCo: JAG1, Pazopanib

Paper: Onvansertib-mediated PLK1 inhibition impairs spermatogenesis in the murine testis.

2026-09-18T00:00:00Z

Published in Asian J Androl on 18 September 2026; matched the OnCo record for EIF4EBP1.

18 September 2026, Asian J Androl.

On OnCo: EIF4EBP1, Onvansertib, PLK1

Paper: Optimizing the Hinge Length of Chimeric Antigen Receptor with a DdFP-Based Immunological Synapse Biosensor.

2026-09-18T00:00:00Z

Published in ACS Sens on 18 September 2026; matched the OnCo record for Mesothelin.

18 September 2026, ACS Sens.

On OnCo: Mesothelin

Paper: Orthodontic Root Resorption in Spontaneously Hypertensive Rats: Modulation by β2-Adrenergic Receptor Blockade.

2026-09-18T00:00:00Z

Published on 18 September 2026 after first appearing as a preprint; matched CT and Androgen receptor.

18 September 2026.

On OnCo: CT, Androgen receptor

Paper: Pemetrexed increases BRCA1 protein stability and sensitizes TNBC cells to radiotherapy.

2026-09-18T00:00:00Z

Published in Oncol Rep on 18 September 2026; matched the OnCo record for Pemetrexed.

18 September 2026, Oncol Rep.

On OnCo: Pemetrexed

Paper: Phthalazine as a medically versatile polyheterocyclic core with underexplored anticancer potential.

2026-09-18T00:00:00Z

Published in J Enzyme Inhib Med Chem on 18 September 2026; matched the OnCo record for PARP.

18 September 2026, J Enzyme Inhib Med Chem.

On OnCo: PARP

Paper: Piceatannol loaded mesenchymal stem cells derived exosomes for cutaneous regenerative treatment of psoriasis-like symptoms in imiquimod-induced mice model: Exosomal hydrogel impact via targeting of JAK3/STAT3 signaling.

2026-09-18T00:00:00Z

Published in Nanomedicine on 18 September 2026; matched the OnCo record for JAK3.

18 September 2026, Nanomedicine.

On OnCo: JAK3

Paper: Plasma cfDNA fragmentomics enables non-invasive detection and preoperative risk stratification of bladder cancer in a multicenter study.

2026-09-18T00:00:00Z

Published in Cancer Lett on 18 September 2026; matched the OnCo record for cfDNA fragmentomics.

18 September 2026, Cancer Lett.

On OnCo: cfDNA fragmentomics

Paper: Plasma signals of lung tumor promotion and the ubiquitous challenge of biomarker specificity.

2026-09-18T00:00:00Z

Published in Diagnosis (Berl) on 18 September 2026; matched the OnCo record for CEACAM5.

18 September 2026, Diagnosis (Berl).

On OnCo: CEACAM5

Paper: PRC2 loss in MPNST is accompanied by SWI/SNF complex rewiring and sensitization to SMARCA2/4 and BET inhibition in vivo.

2026-09-18T00:00:00Z

Published in Mol Cell Proteomics on 18 September 2026; matched the OnCo record for EED.

18 September 2026, Mol Cell Proteomics.

On OnCo: EED, Malignant peripheral nerve sheath tumour, SMARCA2, SUZ12

Paper: Pre-operative magnetic resonance imaging for evaluating depth of invasion in oral tongue cancer: Precision and predictive value.

2026-09-18T00:00:00Z

Published in J Formos Med Assoc on 18 September 2026; matched the OnCo record for Oral tongue and floor of mouth cancer.

18 September 2026, J Formos Med Assoc.

On OnCo: Oral tongue and floor of mouth cancer

Paper: Prevalence and penetrance of heritable retinoblastoma in two adult population cohorts: implications for genomic newborn screening.

2026-09-18T00:00:00Z

Published on 18 September 2026 after first appearing as a preprint; matched Whole-exome & whole-genome sequencing and RB1.

18 September 2026.

On OnCo: Whole-exome & whole-genome sequencing, RB1

Paper: Prognostic value of the Nice Cancer Ageing Survival (NCAS) score in older adults with cancer: A retrospective single institutional study.

2026-09-18T00:00:00Z

Published in J Geriatr Oncol on 18 September 2026; matched the OnCo record for Geriatric assessment.

18 September 2026, J Geriatr Oncol.

On OnCo: Geriatric assessment

Paper: Protocol for identifying cellular and molecular signatures from spatial profiling data using micro-tissue analysis.

2026-09-18T00:00:00Z

Published in STAR Protoc on 18 September 2026; matched the OnCo record for DSP.

18 September 2026, STAR Protoc.

On OnCo: DSP

Paper: Recurrence Patterns of Resected Ampullary Adenocarcinoma and Implications for Multimodal Therapy: A Hidden Genome-Derived Analysis from the Ampullary Cancer Collaborative.

2026-09-18T00:00:00Z

Published in Ann Surg Oncol on 18 September 2026; matched the OnCo record for Ampullary cancer.

18 September 2026, Ann Surg Oncol.

On OnCo: Ampullary cancer

Paper: Regulation of transient receptor potential ankyrin-1 agonist-induced airway epithelial cell injury and repair by protein kinase C and p38 mitogen-activated kinase.

2026-09-18T00:00:00Z

Published in Mol Pharmacol on 18 September 2026; matched the OnCo record for ANK1.

18 September 2026, Mol Pharmacol.

On OnCo: ANK1

Paper: Retraction Note: Buparlisib induces eukaryotic elongation factor-2 expression to cause treatment failure for lung cancer cells.

2026-09-18T00:00:00Z

Published in Mol Genet Genomics on 18 September 2026; matched the OnCo record for Elongation factor 2.

18 September 2026, Mol Genet Genomics.

On OnCo: Elongation factor 2

Paper: Retraction notice to "Smoothened-independent activation of hedgehog signaling by rearranged during transfection promotes neuroblastoma cell proliferation and tumor growth" [Biochim. Biophys. Acta (BBA) - Gen. Subj. 1860 (2016) 1961-1972].

2026-09-18T00:00:00Z

Published in Biochim Biophys Acta Gen Subj on 18 September 2026; matched the OnCo record for Smoothened.

18 September 2026, Biochim Biophys Acta Gen Subj.

On OnCo: Smoothened

Paper: Safety management of anti TROP2 ADCs in patients with breast cancer.

2026-09-18T00:00:00Z

Published in Curr Opin Oncol on 18 September 2026; matched the OnCo record for UGT1A1.

18 September 2026, Curr Opin Oncol.

On OnCo: UGT1A1

Paper: Salvage outcomes with teclistamab after BCMA-directed therapy failure in relapsed/refractory multiple myeloma: a systematic review and meta-analysis.

2026-09-18T00:00:00Z

Published in Curr Probl Cancer on 18 September 2026; matched the OnCo record for Teclistamab.

18 September 2026, Curr Probl Cancer.

On OnCo: Teclistamab

Paper: SDHB deficiency promotes renal fibrosis by triggering mtRNA leakage and activating the RIG-I-MAVS pathway.

2026-09-18T00:00:00Z

Published in Metabolism on 18 September 2026; matched the OnCo record for SDHB.

18 September 2026, Metabolism.

On OnCo: SDHB

Approval: Accelerated approval: Camizestrant (US)

2026-09-04T00:00:00Z

Accelerated approval (Etcamah) The confirmatory requirement was still open 0.0 years later, when the FDA's table was read.

4 September 2026, FDA.

On OnCo: Camizestrant, HR-positive / HER2-negative breast cancer, HR-positive metastatic breast cancer after CDK4/6 inhibitors, Estrogen receptor

Approval: FDA grants accelerated approval to camizestrant with a CDK4/6 inhibitor for ESR1-Mutated HR-positive, HER2-negative locally advanced or metastatic breast cancer

2026-09-04T00:00:00Z

On September 4, 2026, the Food and Drug Administration granted accelerated approval to camizestrant (Etcamah, AstraZeneca), an estrogen receptor antagonist, in combination with a CDK4/6 inhibitor (abemaciclib, palbociclib, or ribociclib) for adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer upon detection of estrogen receptor-1 (ESR1) mutation during aromatase inhibitor and CDK4/6 inhibitor therapy, based on an FDA-authorized test.

4 September 2026, FDA.

On OnCo: Camizestrant, Palbociclib, Abemaciclib, Ribociclib, Breast cancer, HR-positive / HER2-negative breast cancer

Withdrawal: Withdrawal: Adagrasib (US)

2026-09-01T00:00:00Z

Withdrawn: the indication came off the label 2.3 years after its accelerated approval.

1 September 2026, FDA.

On OnCo: Adagrasib, Non-small-cell lung cancer, Colorectal cancer, Pancreatic ductal adenocarcinoma, KRAS G12C-mutant colorectal cancer, KRAS G12C-mutant non-small-cell lung cancer

Approval: Approval: Daraxonrasib (US)

2026-08-26T00:00:00Z

NDA 220910 approved as Rasonque: adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or who are not candidates for multiagent systemic therapy.

26 August 2026, FDA.

On OnCo: Daraxonrasib, Pancreatic ductal adenocarcinoma, Metastatic pancreatic ductal adenocarcinoma, KRAS G12C-mutant pancreatic ductal adenocarcinoma, Non-small-cell lung cancer, Colorectal cancer

Approval: FDA approves daraxonrasib for metastatic pancreatic adenocarcinoma

2026-08-26T00:00:00Z

On August 26, 2026, the Food and Drug Administration approved daraxonrasib (RASONQUE, Revolution Medicines, Inc.), an inhibitor of the RAS GTPase family, for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or who are not candidates for multiagent systemic therapy.

26 August 2026, FDA.

On OnCo: Daraxonrasib, Pancreatic ductal adenocarcinoma, Adenocarcinoma of the urethra, Adenocarcinoma of the lung

Approval: FDA approves zanidatamab-hrii and tislelizumab-jsgr for HER2-positive gastric, gastroesophageal junction, or esophageal adenocarcinoma

2026-08-25T00:00:00Z

On August 25, 2026, the Food and Drug Administration approved zanidatamab-hrii (Ziihera, Jazz Pharmaceuticals) in combination with fluoropyrimidine- and platinum-containing chemotherapy and tislelizumab-jsgr (Tevimbra, BeOne Medicines USA, Inc.), as first-line treatment for adults with HER2-positive (IHC 3+ or IHC 2+/ISH+) unresectable locally advanced or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma, as detected by an FDA-approved test, and in combination with fluoropyrimidine-, and platinum-containing chemotherapy, as first-line treatment for adults with HER2-positive (IHC 3+) unresectable locally advanced or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma, as detected by an FDA-approved test.: dolutegravir.

25 August 2026, FDA.

On OnCo: Tislelizumab, Zanidatamab, Platinum + etoposide, Oesophageal and junctional adenocarcinoma, Adenocarcinoma of the urethra, Adenocarcinoma of the lung, Oesophageal cancer, Gastric & gastro-oesophageal junction cancer, Non-small-cell lung cancer, Hepatocellular carcinoma, Recurrent and metastatic nasopharyngeal carcinoma, Biliary tract cancer, Gallbladder cancer, Biliary tract cancer, HER2

Approval: FDA grants accelerated approval to iberdomide with daratumumab and hyaluronidase-fihj and dexamethasone for multiple myeloma

2026-08-13T00:00:00Z

On August 13, 2026, the Food and Drug Administration granted accelerated approval to iberdomide (Zenbexus, Bristol-Myers Squibb Company) in combination with daratumumab and hyaluronidase-fihj and dexamethasone for adults with multiple myeloma who have received at least one prior line of therapy including a proteasome inhibitor and an immunomodulatory agent.

13 August 2026, FDA.

On OnCo: Dexamethasone, Daratumumab, Iberdomide, Multiple myeloma, Smouldering multiple myeloma, Newly diagnosed multiple myeloma, transplant-eligible, Newly diagnosed multiple myeloma, transplant-ineligible, Plasma cell leukaemia, Acute lymphoblastic leukaemia, Diffuse large B-cell lymphoma, Hodgkin lymphoma

Approval: FDA grants accelerated approval to vusolimogene oderparepvec-wtpg in combination with nivolumab for melanoma

2026-08-06T00:00:00Z

On August 6, 2026, the Food and Drug Administration granted accelerated approval to vusolimogene oderparepvec-wtpg (Tudriqev, Replimune, Inc.), a genetically modified oncolytic viral therapy, in combination with nivolumab for the treatment of adult patients with unresectable advanced cutaneous melanoma who experienced disease progression on a programmed death receptor-1 (PD-1)-blocking antibody-based regimen.

6 August 2026, FDA.

On OnCo: Vusolimogene oderparepvec, Nivolumab, Relatlimab + nivolumab, Melanoma, Non-small-cell lung cancer, Renal cell carcinoma, Hodgkin lymphoma, Colorectal cancer

Approval: Approval: Amivantamab (US)

2026-07-31T00:00:00Z

Subcutaneous formulation (PALOMA-3).

31 July 2026, FDA.

On OnCo: Amivantamab, Non-small-cell lung cancer, EGFR-mutated non-small-cell lung cancer, MET exon 14 and MET-amplified non-small-cell lung cancer, Lung cancer, EGFR, ArteraAI Breast, HR-positive / HER2-negative breast cancer, Atezolizumab, Small-cell lung cancer, Hepatocellular carcinoma, Advanced hepatocellular carcinoma, Bladder & urothelial cancer, Belantamab mafodotin, Multiple myeloma, Relapsed or refractory multiple myeloma, BCMA, Cemiplimab, Melanoma, PD-L1-high non-small-cell lung cancer without a driver mutation, Cutaneous squamous cell carcinoma, Advanced cutaneous squamous cell carcinoma, Durvalumab, Biliary tract cancer, Intrahepatic cholangiocarcinoma, Extrahepatic cholangiocarcinoma, Encorafenib, Colorectal cancer, BRAF V600E-mutant colorectal cancer, BRAF V600E-mutant non-small-cell lung cancer, Lutetium-177 vipivotide tetraxetan, Prostate cancer, Metastatic castration-resistant prostate cancer, Metastatic hormone-sensitive prostate cancer, PSMA, Nivolumab, Renal cell carcinoma, Hodgkin lymphoma, Optune / Optune Pax, Glioma & glioblastoma, Pancreatic ductal adenocarcinoma, Locally advanced unresectable pancreatic ductal adenocarcinoma, Mesothelioma, Pembrolizumab, Mismatch repair deficient (MSI-high) pancreatic ductal adenocarcinoma, Triple-negative breast cancer, Head and neck squamous cell carcinoma, Piflufolastat F-18 / Pylarify TruVu, Relacorilant, Ovarian cancer, Platinum-resistant ovarian cancer, Advanced and metastatic adrenocortical carcinoma, Revumenib, Acute myeloid leukaemia, Acute lymphoblastic leukaemia, NPM1-mutated and KMT2A-rearranged acute myeloid leukaemia, Menin, Satricabtagene autoleucel, Gastric & gastro-oesophageal junction cancer, Claudin 18.2, Tarlatamab, Extensive-stage small-cell lung cancer, Limited-stage small-cell lung cancer, DLL3, Teclistamab, CD3, Trastuzumab deruxtecan, HER2-positive breast cancer, HER2-positive gastric cancer, Vepdegestrant, HR-positive metastatic breast cancer after CDK4/6 inhibitors, Estrogen receptor, Vusolimogene oderparepvec, Advanced melanoma, Zenocutuzumab, KRAS wild-type pancreatic ductal adenocarcinoma, Metastatic pancreatic ductal adenocarcinoma, Zongertinib, HER2-mutant non-small-cell lung cancer, HER2

Approval: FDA approves lutetium Lu 177 vipivotide tetraxetan with androgen receptor pathway inhibitor therapy for metastatic androgen pathway modulation-naïve or -sensitive prostate cancer

2026-07-31T00:00:00Z

On July 31, 2026, the Food and Drug Administration approved lutetium Lu 177 vipivotide tetraxetan (Pluvicto, Novartis Pharmaceuticals Corporation) in combination with androgen receptor pathway inhibitor (ARPI) therapy for adults with prostate-specific membrane antigen (PSMA)-positive metastatic androgen pathway modulation-naïve or-sensitive (mAPMN/S) prostate cancer (previously referred to as metastatic hormone-sensitive prostate cancer).

31 July 2026, FDA.

On OnCo: Lutetium-177 vipivotide tetraxetan, Metastatic hormone-sensitive prostate cancer, Prostate cancer

Approval: FDA approves zidesamtinib for ROS1 -positive non-small cell lung cancer

2026-07-22T00:00:00Z

On July 22, 2026, the Food and Drug Administration approved zidesamtinib (Jideytro, Nuvalent, Inc.) for adults with locally advanced or metastatic ROS1 -positive non-small cell lung cancer (NSCLC) who received at least one prior ROS1 tyrosine kinase inhibitor (TKI).

22 July 2026, FDA.

On OnCo: Zidesamtinib, Lung cancer, Non-small-cell lung cancer, ROS1-positive non-small-cell lung cancer

Approval: FDA approves gedatolisib with fulvestrant, with or without palbociclib, for HR-positive, HER2-negative locally advanced or metastatic breast cancer

2026-07-14T00:00:00Z

On July 14, 2026, the Food and Drug Administration approved gedatolisib (Revtorpyk, Celcuity Inc.) in combination with fulvestrant, with or without palbociclib, for adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer without a PIK3CA mutation detected following progression on or after treatment with at least one line of endocrine therapy in the metastatic setting.

14 July 2026, FDA.

On OnCo: Fulvestrant, Palbociclib, Gedatolisib, Breast cancer, HR-positive / HER2-negative breast cancer, Estrogen receptor, HR-positive metastatic breast cancer after CDK4/6 inhibitors, PIK3CA / PI3K-alpha, AKT, HER2-positive breast cancer, CDK4/6

Withdrawal: Withdrawal: Tazemetostat (US)

2026-06-22T00:00:00Z

Withdrawn: the indication came off the label 6.4 years after its accelerated approval.

22 June 2026, FDA.

On OnCo: Tazemetostat, Follicular lymphoma, Sarcomas, EZH2

Withdrawal: Withdrawal: Tazemetostat (US)

2026-06-22T00:00:00Z

Withdrawn: the indication came off the label 6.0 years after its accelerated approval.

22 June 2026, FDA.

On OnCo: Tazemetostat, Follicular lymphoma, Sarcomas, EZH2

Withdrawal: Withdrawal: Selinexor (US)

2026-04-30T00:00:00Z

Withdrawn: the indication came off the label 5.9 years after its accelerated approval.

30 April 2026, FDA.

On OnCo: Selinexor, Endometrial cancer, Multiple myeloma, Diffuse large B-cell lymphoma, Relapsed or refractory multiple myeloma, TP53

Withdrawal: Withdrawal: Zelenectide pevedotin (US)

2026-03-01T00:00:00Z

Programme deprioritised after regulatory feedback on Duravelo-2 design.

March 2026, FDA.

On OnCo: Zelenectide pevedotin, Bladder & urothelial cancer, Nectin-4

Result: A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor: Phase 3 result

2026-01-01T00:00:00Z

For All Regions Other Than the European Union (EU) and Others Accepting Cycle 2 Day 1: Observed Serum Concentration (Ctrough) of Amivantamab at Steady State: Arm A: Lazertinib With Amivantamab SC-CF 206 micrograms per milliliters (mcg/ml) versus Arm B: Lazertinib With Amivantamab Intravenous (IV) Infusion 144 micrograms per milliliters (mcg/ml).

2026, ClinicalTrials.gov.

On OnCo: A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor, Lazertinib, Non-small-cell lung cancer, Small-cell lung cancer, EGFR-mutated non-small-cell lung cancer

Result: A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair: Phase 3 result

2026-01-01T00:00:00Z

Breast Cancer Gene (BRCA) Subgroup: Radiographic Progression-free Survival (rPFS) Assessed by Investigator: BRCA Subgroup: Placebo With Abiraterone Acetate Plus Prednisone 25.99 months, hazard ratio 0.515.

2026, ClinicalTrials.gov.

On OnCo: A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair, Abiraterone acetate, Niraparib, Prednisone, Prostate cancer, Metastatic hormone-sensitive prostate cancer

Result: A Study of Nofazinlimab (CS1003) in Subjects With Advanced Hepatocellular Carcinoma: Phase 3 result

2026-01-01T00:00:00Z

Overall Survival (OS): Nofazinlimab + Lenvatinib 21.6 months versus Placebo + Lenvatinib 18.5 months.

2026, ClinicalTrials.gov.

On OnCo: A Study of Nofazinlimab (CS1003) in Subjects With Advanced Hepatocellular Carcinoma, Lenvatinib, Hepatocellular carcinoma, Advanced hepatocellular carcinoma

Result: A Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-S: Phase 3 result

2026-01-01T00:00:00Z

Major Pathological Response (MPR) - IASLC Method: Osimertinib + Chemo 25.6 % versus Osimertinib 24.8 % versus Placebo + Chemo 1.7 %.

2026, ClinicalTrials.gov.

On OnCo: A Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-S, Osimertinib, Cisplatin, Carboplatin, Pemetrexed, Non-small-cell lung cancer

Result: A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma: Phase 3 result

2026-01-01T00:00:00Z

Adjusted Time-Averaged Nivolumab Serum Concentration Over the First 28 Days (Cavgd28-Nivo) on Natural Logarithmic Scale: Nivo + Rela FDC SC 4.141 ug/ml versus Nivo + Rela FDC IV 3.901 ug/ml.

2026, ClinicalTrials.gov.

On OnCo: A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma, Nivolumab, Relatlimab + nivolumab, Melanoma, Advanced melanoma

Result: A Study of Subcutaneous Nivolumab Versus Intravenous Nivolumab in Participants With Previously Treated Clear Cell Renal Cell Carcinoma That is Advance: Phase 3 result

2026-01-01T00:00:00Z

Adjusted Geometric Mean Serum Concentration of Nivolumab Over 28 Days (Cavgd28) on Original Scale: Nivolumab SC 77.373 μg/ml versus Nivolumab IV 36.875 μg/ml versus Nivo SC Process C 75.504 μg/ml versus Nivo SC Process D 75.596 μg/ml.

2026, ClinicalTrials.gov.

On OnCo: A Study of Subcutaneous Nivolumab Versus Intravenous Nivolumab in Participants With Previously Treated Clear Cell Renal Cell Carcinoma That is Advance, Nivolumab, Renal cell carcinoma, Clear cell renal cell carcinoma

Result: A Study to Evaluate Chemotherapy Plus Osimertinib Against Chemotherapy Plus Placebo in Patients With Non-small Cell Lung Cancer: Phase 3 result

2026-01-01T00:00:00Z

Progression Free Survival (PFS): Treatment Arm A: Osimertinib (AZD9291), Pemetrexed, Cisplatin or Carboplatin 8.4 months versus Treatment Arm B: Placebo for Osimertinib (AZD9291), Pemetrexed, Cisplatin or Carboplatin 4.4 months, hazard ratio 0.43.

2026, ClinicalTrials.gov.

On OnCo: A Study to Evaluate Chemotherapy Plus Osimertinib Against Chemotherapy Plus Placebo in Patients With Non-small Cell Lung Cancer, Osimertinib, Non-small-cell lung cancer, Small-cell lung cancer

Result: A Study to Investigate Tolerability and Efficacy of Asciminib: Phase 3 result

2026-01-01T00:00:00Z

Time to Discontinuation of Study Treatment Due to Adverse Event (TTDAE) (From Interim Analysis): Asciminib 16 participants versus Nilotinib 34 participants, hazard ratio 0.45.

2026, ClinicalTrials.gov.

On OnCo: A Study to Investigate Tolerability and Efficacy of Asciminib, Asciminib, Nilotinib, Chronic myeloid leukaemia, Chronic myeloid leukaemia, chronic phase

Result: ALTAIR: Phase 3 result

2026-01-01T00:00:00Z

Median disease-free survival 9.30 against 5.55 months (hazard ratio 0.79, p=0.107): primary endpoint not met.

2026, DOI.

On OnCo: ALTAIR, Trifluridine/tipiracil, Signatera, Colorectal cancer

Result: An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomi: Phase 3 result

2026-01-01T00:00:00Z

Red Blood Cell-transfusion Independence (RBC-TI) ≥ 12 Weeks (RBC-TI 12): Treatment 23.08 % versus Control 13.33 %.

2026, ClinicalTrials.gov.

On OnCo: An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomi, Luspatercept, Myeloproliferative neoplasms, Primary myelofibrosis

Result: BL-B01D1-307: Phase 3 result

2026-01-01T00:00:00Z

PFS and OS significantly improved at interim analysis (numbers presented ASCO 2026).

2026, onclive.com.

On OnCo: BL-B01D1-307, Izalontamab brengitecan, Triple-negative breast cancer

Result: Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC: Phase 3 result

2026-01-01T00:00:00Z

Overall survival 17.7 vs 18.0 months (HR 0.92, p 0.32) overall and 20.4 vs 20.4 months (HR 1.05) in PIK3CA/AKT1/PTEN-altered tumours; PFS 5.6 vs 5.1 months (HR 0.72).

2026, DOI.

On OnCo: Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC, Capivasertib, Paclitaxel / nab-paclitaxel, Triple-negative breast cancer, Metastatic triple-negative breast cancer

Result: CLARITY-Gastric 01: Phase 3 result

2026-01-01T00:00:00Z

Co-primary endpoints including OS met (July 2026); numbers pending.

2026, cancernetwork.com.

On OnCo: CLARITY-Gastric 01, Sonesitatug vedotin, Ramucirumab, Gastric & gastro-oesophageal junction cancer, Claudin 18.2

Result: DeLLphi-305: Phase 3 result

2026-01-01T00:00:00Z

Met the primary overall survival endpoint at the pre-specified interim analysis (Amgen, 8 September 2026); progression-free survival and response rate also improved; figures not yet disclosed.

2026, amgen.com.

On OnCo: DeLLphi-305, Tarlatamab, Durvalumab, Small-cell lung cancer, Extensive-stage small-cell lung cancer, DLL3

Result: DREAM3R: Phase 3 result

2026-01-01T00:00:00Z

Stopped early; primary endpoint not met.

2026, ClinicalTrials.gov.

On OnCo: DREAM3R, Durvalumab, Pemetrexed, Mesothelioma

Withdrawal: EU withdrawal: Duvelisib

2026-01-01T00:00:00Z

Marketing authorisation withdrawn in the European Union in 2026: Authorised May 2021; marketing authorisation withdrawn at Secura Bio's request 16 Feb 2026 (commercial reasons).

2026, European Commission (EMA opinion).

On OnCo: Duvelisib, Chronic lymphocytic leukaemia, Peripheral T-cell lymphomas, PIK3CA / PI3K-alpha

Withdrawal: EU withdrawal: Cinacalcet

2025-01-01T00:00:00Z

Marketing authorisation withdrawn in the European Union in 2025: Mimpara: authorised 22 Oct 2004; marketing authorisation withdrawn 18 Dec 2025.

2025, European Commission (EMA opinion).

On OnCo: Cinacalcet, Parathyroid carcinoma

Withdrawal: EU withdrawal: Lifileucel

2025-01-01T00:00:00Z

Marketing authorisation withdrawn in the European Union in 2025: MAA withdrawn 22 Jul 2025 after CHMP signalled a negative opinion (response rate, deaths, manufacturing).

2025, European Commission (EMA opinion).

On OnCo: Lifileucel, Melanoma, Non-small-cell lung cancer, Advanced melanoma

Law: European Health Data Space Regulation (EU) 2025/327

2025-01-01T00:00:00Z

A 2025 EU regulation that gives patients electronic access to their health records across the Union and creates national bodies that can grant researchers, regulators and companies permission to use anonymised or pseudonymised health data, phased in over the rest of the decade.

2025, European Union, regulation.

On OnCo: European Health Data Space Regulation (EU) 2025/327, GDPR and health data, Oncology EHR and real-world data platforms, Real-world evidence

OnCo Edge

Paper: Benefit from perioperative enfortumab vedotin-pembrolizumab in cisplatin-eligible MIBC.

Paper: HCT-ASCT confirmed as standard-of-care consolidation therapy for PCNSL.

Approval: FDA approves belzutifan in combination with lenvatinib for advanced renal cell carcinoma with a clear cell component

Approval: FDA approves lirafugratinib for previously treated, unresectable, locally advanced or metastatic cholangiocarcinoma

Issue: OnCo weekly, 2026-10-03

Proposal: Proposed approval: Aspirin

Proposal: Proposed new product: Casgevy

Proposal: Proposed new product: Cystagon

Proposal: Proposed new product: Entyvio

Proposal: Proposed new product: Libmeldy

Proposal: Proposed new product: Lumeblue

Proposal: Proposed new product: Lynkuet

Proposal: Proposed new product: NeoRecormon

Proposal: Proposed new product: Nezglyal

Proposal: Proposed new product: Procysbi

Proposal: Proposed new product: SomaKit TOC

Proposal: Proposed new product: Strimvelis

Proposal: Proposed new product: Waskyra

Proposal: Proposed new product: Xromi

Proposal: Proposed new product: Yartemlea

Proposal: Proposed new product: Zefylti

Proposal: Proposed trial status change: ALKOVE-1

Proposal: Proposed trial status change: Alliance A071401

Proposal: Proposed trial status change: AUGMENT-101

Proposal: Proposed trial status change: Bonner trial

Issue: OnCo weekly, 2026-10-02

Paper: Erratum: Five-Year Outcomes of Short-Term Radiotherapy Plus Chemotherapy Versus Long-Term Chemoradiotherapy for Locally Advanced Rectal Cancer: Updated Results of the STELLAR Trial.

Approval: FDA approves imlunestrant in combination with abemaciclib for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer

Paper: [Clues for identifying Diamond-Blackfan anemia among infants with early severe anemia: Clinical and genetic analysis of 11 cases].

Paper: Adolescent health across Asia Pacific, 2000-23: a systematic analysis for the Global Burden of Disease Study 2023.

Paper: Analysis of end-stage renal disease mediated by cuproptosis-related genes.

Paper: Approaches to thyroid nodules in paediatric cancer predisposition syndromes.

Paper: ASO Visual Abstract: A Prospective Multicenter Comparative Cohort Study of Neoadjuvant Sintilimab Plus Chemotherapy and Chemoradiotherapy in Resectable Clinical Node-Positive Esophageal Squamous Cell Carcinoma.

Paper: ASO Visual Abstract: Mex3a Stabilizes INHBB mRNA to Activate SMAD-Signaling and Promote Hepatocellular Carcinoma Metastasis.

Paper: ASO Visual Abstract: Prognostic Value of Intratumoral Expression of Claudin 18.2 in Resected Pancreatic Cancer.

Paper: ASO Visual Abstract: Treatment for Oligo-recurrence of Diffuse Pleural Mesothelioma After Extended Pleurectomy/Decortication.

Paper: Association Between Danish Guideline Treatments for Breast Cancer and Physiotherapy-Relevant Late Effects: A Nationwide Cohort Study.

Paper: ATP Release and Purinergic Signaling Potentiate β-Adrenergic Effects on Brown Adipocytes.

Paper: Blinatumomab-induced catastrophic immune effector cell-associated neurotoxicity with diffuse cerebral edema in a patient with ALL: Case report.

Paper: Cell Type-Specific Roles of TBK1 in Steatotic Liver Disease: Evidence for an Inflammatory TBK1<sup>+</sup>CASP1<sup>+</sup> Kupffer Cell State.

Paper: Commissioning and end-to-end validation of a combined surface-guided and triggered kV imaging workflow for breath-hold SBRT on a Varian TrueBeam.

Paper: Conformational stability and domain-specific structural features of tumor autoantigens regulate autoantibody epitope propensity.

Paper: Correction to 'FOLFOX Versus FOLFIRI as Second-Line Chemotherapy in Patients With Advanced Biliary Tract Cancers: A Multicenter, Italian Study'.

Paper: Cross-Talk Between Histamine H<sub>2</sub> Receptor and Glucocorticoid Receptor: Potential Implications in Acute Myeloid Leukemia Treatment.

Paper: CX3CR1 Modulates Migration of Resident Microglia Towards Cortical Laser-Induced Lesions.

Paper: Effects of curcumin and nicorandil on nilotinib-induced QT interval prolongation in rats: A telemetry-based study.

Paper: Effects of Progressive Inspiratory Muscle Training on Lung Volume and Respiratory Strength in Patients With Pre-Dialysis Chronic Kidney Disease.

Paper: Elevated Expression of Caveolin-1 Reflects a Poor Prognosis in Patients With Primary Central Nervous System Lymphomas.

Paper: Engineering a protein homodimer from a heterodimer: A chimeric DBHS protein.

Paper: Estradiol Promotes Tumor Progression in ERα-Low Endometrial Cancer via the GPER/SphK1 Pathway.

Paper: Evaluation of interfractional shift corrections in Gamma Knife radiosurgery.

Paper: External validation of the NADIR model for early prostate-specific antigen response prediction in enzalutamide-treated metastatic hormone-sensitive prostate cancer: An analysis of the ARCHES trial.

Paper: Feasibility of lattice radiation therapy using a noncoplanar vertex arrangement and dynamic conformal arcs.

Paper: Fertility-Sparing Treatment of Endometrial Cancer: Survey of Australian Practice.

Paper: FOCS-24: An integrated oncologic-functional endpoint and its preoperative nomogram after focal therapy for localized prostate cancer.

Paper: Fruquintinib: Mechanism of Action, Clinical, and Translational Science.

Paper: Gender-Specific Cancer-Related Survival Analysis of Robotic Versus Laparoscopic Low Anterior Resection for Rectal Adenocarcinoma: A Multicenter Study.

Paper: Ginsenosides Rb1 and Rg1 Suppress Lipopolysaccharide-Induced Inflammatory Gene Expression in Microglia and Astrocytes, Unlike Rb2.

Paper: Gut Microbiome Diversity, Functional Potential, and Ecological Relevance of Hottentotta tamulus.

Paper: Immune Checkpoint Inhibitor-Associated Hemophagocytic Lymphohistiocytosis: Clinical Presentation and Outcomes in Three Patients.

Paper: Impact of post-chemotherapy classification on outcomes in stage III and IV unilateral favorable histology Wilms tumor: Pooled data from Children's Oncology Group AREN0532, AREN0533, and AREN03B2 studies.

Paper: Inhibition of Acetylation Activity of p300/CBP Ameliorates Hepatic Steatosis Through Downregulation of ACSL4.

Paper: Insulin autoimmune syndrome (Hirata Disease): An updated review of epidemiology, pathophysiology, clinical features, diagnosis, and management.

Paper: Integrated Assessment of Sarcopenia in Patients with Gastric Cancer Using Deep Learning and Radiomics.

Paper: Integrated omics-driven discovery reveals synphilin-1-mediated anoikis resistance through p53 down-regulation.

Paper: Macrophage FOXO1 Inhibition Protects Against Hyperglycaemia-Associated Kidney Injury.

Paper: Management of Hemangiomas.

Paper: MiR-376c-3p Targets STRBP mRNA to Regulate Cashmere Goat Hair Follicle Stem Cell Proliferation and Multipotency by Inhibiting the Wnt/β-Catenin and BMP Signaling Pathways.

Paper: New Observations on a Low-Grade Diffusely Infiltrative Tumour, SMARCB1 Mutant, Arguing for a New Tumour Type.

Paper: Non-Meningothelial Mesenchymal Tumor of the Central Nervous System: Case Report and Literature Review.

Paper: Nutritional Indexes and Their Variations as Predictors of Atezolizumab Plus Chemotherapy Efficacy in Extensive-Stage Small Cell Lung Cancer: A Turkish Oncology Group Study.

Issue: OnCo weekly, 2026-10-01

Paper: Oral vitamin C supplementation in patients with clonal cytopenia of undetermined significance or lower-risk myeloid malignancies: Results from EVITA, a phase 2 randomized, placebo-controlled trial.

Paper: Pancreatic Cancer Disrupts Circadian Patterns of Gene Expression in Cardiorespiratory Muscles.

Paper: Precision Oncology in Soft Tissue Sarcomas and Gastrointestinal Stromal Tumors.

Paper: Predicting Relevant Microglia-Associated Cell-Cell Communication Pathways in Alzheimer's Disease: A Role for SPP1.

Paper: Prevalence and Clinical Significance of Abnormal Findings on Pre-Diagnostic Imaging in Pancreatic Ductal Adenocarcinoma.

Paper: Primary Cerebral Pleomorphic-Myxoid Sarcoma With Many Hyaline Globules.

Paper: Primary pulmonary salivary gland-type tumors in cytopathology practice: A systematic review and meta-analysis.